CRISPR / Cas12b gene editing system based on NiCas12b protein and related application of CRISPR / Cas12b gene editing system
By splitting the NiCas12b protein into its N-terminus and C-terminus and fusing them with its integrins, a fusion protein that can be packaged into AAV virus was formed, solving the off-target effects and packaging problems of the CRISPR/Cas12b system and achieving highly specific and highly active gene editing effects.
Patent Information
- Application Number
- CN202411019224.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-08
AI Technical Summary
Existing CRISPR/Cas12b gene editing systems suffer from off-target effects, leading to the incorrect editing of non-target sequences. Furthermore, the NiCas12b protein is difficult to package into AAV viruses due to its large gene size, which limits the scope and specificity of gene editing.
The NiCas12b protein is truncated into two fragments, NiCas12b-N-terminus and NiCas12b-C-terminus, which are then fused with the N-terminus and C-terminus of the inteptide to form NiCas12b-N-terminal fusion protein and NiCas12b-C-terminal fusion protein, respectively. These fragments can be packaged into AAV virus, expressed in cells, and form the complete NiCas12b protein, which then binds to sgRNA for gene editing.
It achieves highly specific and highly active gene editing, expands the scope of gene editing, and improves the specificity of editing, making it suitable for efficient gene editing in a variety of eukaryotic cell environments.
Smart Images

Figure CN118910006A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of gene editing technology, and specifically to NiCas12b protein, NiCas12b-based fusion protein, CRISPR / Cas12b gene editing system based on the protein, and related applications for gene editing. Background Art
[0002] The CRISPR / Cas12b system is an acquired immune system evolved by bacteria and archaea to resist invasion by exogenous viruses or plasmids. The CRISPR / Cas12b system contains tracrRNA (trans-activating RNA) and crRNA (CRISPR-derived RNA), which together with Cas12b form a complex to function. TracrRNA and crRNA can be fused into single-stranded guide RNA (sgRNA) through a connecting sequence. After the genomic DNA in eukaryotic cells is broken and damaged by this system, the two main DNA damage repair mechanisms in the cell are responsible for repair: non-homologous end-joining (NHEJ) and homologous recombination (HR). The result of NHEJ repair will cause the deletion or insertion of bases, which can be used for gene knockout; when a homologous template is provided, HR repair can be used for site-specific insertion of genes and precise replacement of bases.
[0003] In addition to basic scientific research, the CRISPR / Cas12b gene editing system also has broad clinical application prospects. However, almost all CRISPR / Cas have off-target effects, which can lead to incorrect editing of non-target sequences. Therefore, the current important research direction in this field is to discover editing tools with higher specificity to reduce off-target effects. In addition, since the previously discovered Cas12b gene is relatively large (>4.7kb), the possibility of packaging the editing system using the Cas12b gene into AAV is greatly reduced.
[0004] Therefore, it is necessary to develop a gene editing system with high editing activity, high specificity, simple PAM sequence, and the ability to be packaged into AAV, so as to expand the scope of gene editing and improve the specificity of gene editing. Summary of the invention
[0005] The inventors found in the study that NiCas12b protein was truncated into two protein fragments, i.e. NiCas12b-N-terminal including the 1st-756th amino acid sequence of NiCas12b protein and NiCas12b-C-terminal including the 757th-1439th amino acid sequence of NiCas12b protein, and respectively with the N-terminal (intein-N, SEQ ID NO: 11) and C-terminal (intein-C, SEQ ID NO: 12) of the intein from point-shaped star moss algae (Nostoc punctiforme) fused, thus obtaining two kinds of fusion proteins (referred to as NiCas12b-N-terminal fusion protein and NiCas12b-C-terminal fusion protein), which can be packaged into AAV virus respectively, and the AAV virus can be expressed in cells, mice, etc. after transduction into cells, and complete NiCas12b protein is formed by means of the effect of intein, so as to play a gene editing effect together with corresponding sgRNA. Thus the present invention is realized.
[0006] In summary, in the first aspect of the present invention, a fusion protein is provided, comprising:
[0007] a) the NiCas12b protein N-terminus and the intein N-terminus whose amino acid sequence is represented by positions 1-756 of SEQ ID NO: 1; or
[0008] b) The C-terminus of the NiCas12b protein and the C-terminus of the intein whose amino acid sequence is represented by positions 757-1439 of SEQ ID NO: 1.
[0009] In a second aspect, the present invention provides a conjugate comprising:
[0010] a) the fusion protein described in the first aspect;
[0011] b) a detectable label and / or an additional protein or polypeptide; and
[0012] c) optionally a linker for connecting the fusion protein to the detectable label or the additional protein or polypeptide.
[0013] In a third aspect, the present invention provides a single-stranded guide RNA, wherein the single-stranded guide RNA comprises a scaffold sequence and a CRISPR spacer sequence from the 5' end to the 3' end, wherein the scaffold sequence is:
[0014] a) a scaffold sequence shown in SEQ ID NO: 7 or SEQ ID NO: 9;
[0015] b) a sequence modified based on the sequence shown in SEQ ID NO: 7 or SEQ ID NO: 9 and retaining its biological activity.
[0016] In a fourth aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein of the first aspect or the conjugate of the second aspect.
[0017] In a fifth aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the single-stranded guide RNA described in the third aspect.
[0018] In a sixth aspect, the present invention provides a vector comprising a nucleic acid sequence encoding the fusion protein of the first aspect or the conjugate of the second aspect.
[0019] In a seventh aspect, the present invention provides a vector comprising a nucleic acid sequence encoding the single-stranded guide RNA described in the third aspect.
[0020] In an eighth aspect, the present invention provides a CRISPR / Cas12b gene editing system comprising:
[0021] 1) A protein component comprising:
[0022] a) the fusion protein described in a) of the first aspect or the corresponding conjugate described in the second aspect, and the fusion protein described in b) of the first aspect or the corresponding conjugate described in the second aspect; or
[0023] b) a NiCas12b protein having an amino acid sequence as shown in SEQ ID NO: 1, or a conjugate or fusion protein thereof;
[0024] as well as
[0025] 2) the single-stranded guide RNA described in the third aspect;
[0026] Furthermore, the protein component and the single-stranded guide RNA bind to each other to form a complex;
[0027] Wherein, the conjugate of the NiCas12b protein comprises: NiCas12b protein; a detectable marker, or a combination of a detectable marker and another protein or polypeptide; and an optional linker for connecting the fusion protein to the detectable marker;
[0028] Wherein, the fusion protein of the NiCas12b protein comprises: NiCas12b protein; other proteins and polypeptides; and optionally a linker for connecting the fusion protein with the other proteins and polypeptides.
[0029] In a ninth aspect, the present invention provides a method for gene editing a target sequence in a cell or in vitro environment, the method comprising: contacting any one of the following (1) to (4) with the target sequence in the cell or in vitro environment:
[0030] (1) the fusion protein described in a) of the first aspect or the corresponding conjugate described in the second aspect, the fusion protein described in b) of the first aspect or the corresponding conjugate described in the second aspect, and the single-stranded guide RNA described in the third aspect;
[0031] (2) the isolated nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein described in a) of the first aspect or the corresponding conjugate described in the second aspect as described in the fourth aspect, the isolated nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein described in b) of the first aspect or the corresponding conjugate described in the second aspect as described in the fourth aspect, and the isolated nucleic acid molecule as described in the fifth aspect;
[0032] (3) the vector according to aspect 6 comprising a nucleic acid sequence encoding the fusion protein according to aspect a) of aspect 1 or the corresponding conjugate according to aspect 2, the vector according to aspect 6 comprising a nucleic acid sequence encoding the fusion protein according to aspect b) of aspect 1 or the corresponding conjugate according to aspect 2, and the vector according to aspect 7;
[0033] (4) The CRISPR / Cas12b gene editing system described in the eighth aspect;
[0034] Wherein, the conjugate or the fusion protein recognizes a protospacer-adjacent sequence located at the 5' end of the target sequence and having the sequence 5'-TTN.
[0035] In a tenth aspect, the present invention provides a method for expressing a NiCas12b protein having an amino acid sequence as shown in SEQ ID NO: 1 in a cell or in vitro environment, comprising using the following (1) or (2):
[0036] (1) the isolated nucleic acid molecule of the fourth aspect comprising a nucleic acid sequence encoding the fusion protein of the first aspect a) or the corresponding conjugate of the second aspect, and the isolated nucleic acid molecule of the fourth aspect comprising a nucleic acid sequence encoding the fusion protein of the first aspect b) or the corresponding conjugate of the second aspect; or
[0037] (2) The vector of the sixth aspect comprising a nucleic acid sequence encoding the fusion protein of the first aspect a) or the corresponding conjugate of the second aspect, and the vector of the sixth aspect comprising a nucleic acid sequence encoding the fusion protein of the first aspect b) or the corresponding conjugate of the second aspect.
[0038] In the eleventh aspect, the present invention provides a cell, comprising: the isolated nucleic acid molecule described in the fourth aspect or the fifth aspect, or the vector described in the sixth aspect or the seventh aspect.
[0039] In a twelfth aspect, the present invention provides a kit for gene editing a target sequence in a cell or in vitro environment, comprising:
[0040] a) Any one selected from the following (1) to (4):
[0041] (1) the fusion protein described in a) of the first aspect or the corresponding conjugate described in the second aspect, the fusion protein described in b) of the first aspect or the corresponding conjugate described in the second aspect, and the single-stranded guide RNA described in the third aspect;
[0042] (2) the isolated nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein described in a) of the first aspect or the corresponding conjugate described in the second aspect as described in the fourth aspect, the isolated nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein described in b) of the first aspect or the corresponding conjugate described in the second aspect as described in the fourth aspect, and the isolated nucleic acid molecule as described in the fifth aspect;
[0043] (3) the vector according to aspect 6 comprising a nucleic acid sequence encoding the fusion protein according to aspect a) of aspect 1 or the corresponding conjugate according to aspect 2, the vector according to aspect 6 comprising a nucleic acid sequence encoding the fusion protein according to aspect b) of aspect 1 or the corresponding conjugate according to aspect 2, and the vector according to aspect 7;
[0044] (4) The CRISPR / Cas12b gene editing system described in the eighth aspect;
[0045] as well as
[0046] b) Instructions for performing gene editing on the target sequence in cells or in vitro.
[0047] The inventors have developed a CRISPR / Cas12b editing tool suitable for efficient gene editing in a variety of eukaryotic cell environments. The CRISPR / Cas12b gene editing tool uses NiCas12b protein and sgRNA or its improved sgRNA variants, showing high specificity, high editing activity, PAM and other characteristics. In addition, the inventors also split the NiCas12b protein into two protein fragments at the N-terminus and the C-terminus, and then fuse the two protein fragments with the N-terminus and C-terminus fragments of the intein, respectively, and the two fusion proteins thus obtained can be packaged by vector tools such as adeno-associated viruses, and are expressed in cells, mice, etc. and form a complete NiCas12b protein to play a gene editing role, solving the problem that NiCas12b is difficult to be packaged by vector tools such as adeno-associated viruses due to large genes. The technical solution of the present invention is very suitable for later development as a gene therapy tool. BRIEF DESCRIPTION OF THE DRAWINGS
[0048] In order to more clearly illustrate the specific implementation of the present invention or the technical solution in the prior art, the drawings required for use in the specific implementation or the description of the prior art are briefly introduced below.
[0049] Figure 1 The editing efficiency of the A3 target site by the CRISPR / NiCas12b system involving single-stranded guide RNAs with different spacer lengths according to an embodiment of the present invention is shown.
[0050] Figure 2 Schematic diagrams of the secondary structures of the wild-type sgRNA (WT) and sgRNA variants (V1-V4) according to embodiments of the present invention are shown.
[0051] Figure 3 The editing efficiency of the A3 target site by the CRISPR / NiCas12b system including the wild-type sgRNA (WT) and sgRNA variants (V1-V4) according to an embodiment of the present invention is shown.
[0052] Figure 4 The specific detection results of the CRISPR / NiCas12b gene editing system according to an embodiment of the present invention in the GFP reporter system HEK293T cell line containing the target sequence are shown.
[0053] Figure 5 A schematic diagram of the construction of plasmids expressing NiCas12b-N-terminal fusion protein and NiCas12b-C-terminal fusion protein according to an embodiment of the present invention is shown.
[0054] Figure 6The editing efficiency of the Pcsk9 target site by the CRISPR / NiCas12b system involving intact NiCas12b proteins obtained from fusion proteins obtained by different cleavage methods and fully expressed NiCas12b proteins is shown.
[0055] Figure 7 The expression of PCSK9 protein under the action of the CRISPR / NiCas12b system involving a complete NiCas12b protein assembled from fusion proteins obtained by different cleavage methods and a fully expressed NiCas12b protein is shown. DETAILED DESCRIPTION
[0056] Hereinafter, the present invention will be described in detail with reference to the accompanying drawings. It should be understood that the following description is only used to illustrate the present invention by way of example, and is not intended to limit the scope of the present invention. The scope of protection of the present invention shall be subject to the attached claims. In addition, those skilled in the art will understand that the technical solution of the present invention may be modified without departing from the spirit and purpose of the present invention. Unless otherwise specified, the technical means used in the embodiments are conventional means well known to those skilled in the art.
[0057] definition
[0058] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the subject matter described herein belongs. Before describing the present invention in detail, the following definitions are provided for a better understanding of the present invention.
[0059] Where a numerical range is provided, such as a concentration range, a percentage range, or a ratio range, it is understood that each intervening value to one-tenth of the unit of the lower limit between the upper and lower limits of the range and any other stated or intervening values in the stated range are included in the subject matter unless the context clearly dictates otherwise. The upper and lower limits of these smaller ranges may be independently included in the smaller ranges, and such embodiments are also included in the subject matter, subject to any specifically excluded limit in the stated range. Where the stated range includes one or two limits, ranges excluding either or both of those included limits are also included in the subject matter.
[0060] In the context of the present invention, many embodiments use the expressions "comprising", "including" or "consisting essentially / mainly of..." The expressions "comprising", "including" or "consisting essentially / mainly of..." can usually be understood as open-ended expressions, indicating that in addition to the elements, components, assemblies, method steps, etc. specifically listed after the expression, other elements, components, assemblies, method steps, etc. are also included. In addition, in this article, the expressions "comprising", "including" or "consisting essentially / mainly of..." can also be understood as closed expressions in some cases, indicating that only the elements, components, assemblies, method steps specifically listed after the expression are included, and no other elements, components, assemblies, method steps are included. At this time, the expression is equivalent to the expression "consisting of..."
[0061] In order to better understand the present teachings and not to limit the scope of the present teachings, unless otherwise indicated, all numbers and other numerical values used in the specification and claims indicating quantities, percentages or ratios should be understood as being modified by the term "about" in all cases. Therefore, unless otherwise indicated, the numerical parameters set forth in the following specification and the appended claims are approximate values, which may vary depending on the desired properties sought to be obtained. At a minimum, each numerical parameter should at least be interpreted in light of the number of reported significant digits and by applying ordinary rounding techniques.
[0062] The terms "Cas12b protein", "Cas12b" and "Cas" used herein are used interchangeably in this application and refer to RNA-guided nucleases including Cas12b protein or its functionally active fragments. Cas12b protein is a protein component of the CRISPR / Cas12b genome editing system, which can target and cut DNA target sequences under the guidance of single-stranded guide RNA (gRNA) to form DNA double-strand breaks (DSBs). DNA double-strand breaks can activate the intrinsic repair mechanisms non-homologous end joining (NHEJ) and homologous recombination (HR) in cells, thereby repairing DNA damage in cells. During the repair process, the specific DNA sequence is edited at the site.
[0063] The terms "single-stranded guide RNA (guide RNA)", "gRNA", "sgRNA (single guided RNA)" or "mature crRNA" used herein are used interchangeably in this application and have the meanings generally understood by those skilled in the art. In general, a single-stranded guide RNA may include a scaffold sequence and a guide sequence, which is also referred to herein as a guide RNA (guide RNA or gRNA). In the context of an endogenous CRISPR system, a guide sequence is also referred to as a spacer. In some cases, a guide sequence is any polynucleotide sequence that has sufficient similarity to a target sequence to hybridize with the target sequence and guide the specific binding of a CRISPR / Cas9 complex to the target sequence. In certain embodiments, when optimally aligned, the degree of complementarity between a guide sequence and its corresponding target sequence is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%. Determining optimal alignment is within the capabilities of a person of ordinary skill in the art. For example, there are open and commercially available alignment algorithms and programs, such as but not limited to ClustalW, Smith-Waterman algorithm (Smith-Waterman), Bowtie, Geneious, Biopython and SeqMan in matlab. The term "CRISPR / Cas12 complex" as used herein refers to a complex formed by the combination of single-stranded guide RNA (single guide RNA) or mature crRNA and NiCas12b protein or its mutant protein, which comprises a guide sequence that hybridizes with a target sequence and thus binds NiCas12b protein to the target sequence. The complex can recognize and cut polynucleotides that can hybridize with the single-stranded guide RNA.
[0064] The term "CRISPR / Cas12b complex" as used herein refers to a complex formed by the binding of a single-stranded guide RNA (single guideRNA) or a mature crRNA:tracrRNA hybrid to a Cas12b protein, which comprises a guide sequence that hybridizes with a target sequence and thereby binds the Cas12b protein to the target sequence. The complex is capable of recognizing and cleaving a polynucleotide that can hybridize with the single-stranded guide RNA or mature crRNA.
[0065] Therefore, in the case of forming CRISPR / Cas12b complex, "target sequence" refers to a polynucleotide targeted by a guide sequence designed to have targeting, such as a sequence complementary to the guide sequence, wherein the hybridization between the target sequence and the guide sequence will promote the formation of CRISPR / Cas12b complex. Complete complementarity is not necessary, as long as there is enough complementarity to cause hybridization and promote the formation of CRISPR / Cas12b complex. The target sequence can include any polynucleotide, such as DNA. In some cases, the target sequence is located in the nucleus or cytoplasm of the cell. In some cases, the target sequence may be located in an organelle of a eukaryotic cell such as mitochondria or chloroplasts.
[0066] The term "target sequence" or "target polynucleotide" as used herein can be any endogenous or exogenous polynucleotide for a cell (e.g., a eukaryotic cell). For example, the target polynucleotide can be a polynucleotide present in the nucleus of a eukaryotic cell. The target polynucleotide can be a sequence encoding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or a useless DNA). In some cases, the target sequence should be related to a protospacer adjacent motif (PAM). The precise sequence and length requirements for PAM vary depending on the Cas protein used, but PAM is typically a 2-5 base sequence adjacent to the protospacer (target sequence). Those skilled in the art can identify the PAM sequence used with a given Cas protein.
[0067] As used herein, the terms "polynucleotide", "nucleic acid sequence", "nucleotide sequence" or "nucleic acid fragment" are used interchangeably and are single-stranded or double-stranded RNA or DNA polymers that optionally may contain synthetic, non-natural or altered nucleotide bases. Nucleotides are referred to by their single letter names as follows: "A" is adenosine or deoxyadenosine (RNA or DNA, respectively), "C" represents cytidine or deoxycytidine, "G" represents guanosine or deoxyguanosine, "U" represents uridine, "T" represents deoxythymidine, "R" represents purine (A or G), "Y" represents pyrimidine (C or T), "K" represents G or T, "H" represents A or C or T, "I" represents inosine, and "N" represents any nucleotide.
[0068] In the sequences used in the present invention, degenerate bases are sometimes used to represent bases at one or more positions. Degenerate bases can be represented by letters R, Y, M, K, S, W, H, B, V, D, and N, wherein R represents A / G, Y represents C / T, M represents A / C, K represents G / T, S represents C / G, W represents A / T, H represents A / T / C, B represents G / T / C, V represents G / A / C, D represents G / A / T, and N represents A / T / C / G.
[0069] As used herein, the terms "polypeptide", "peptide", and "protein" are used interchangeably in this application to refer to polymers of amino acid residues. The term is applicable to amino acid polymers in which one or more amino acid residues are artificial chemical analogs of the corresponding naturally occurring amino acids, and to naturally occurring amino acid polymers. The terms "polypeptide", "peptide", "amino acid sequence" and "protein" may also include modified forms, including but not limited to glycosylation, lipid attachment, sulfation, gamma carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation.
[0070] The term "vector" as used herein refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When the vector can express the protein encoded by the inserted polynucleotide, or when the vector can transcribe the inserted polynucleotide (e.g., transcribe to generate mRNA or functional RNA), the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements it carries are expressed in the host cell. Vectors are well known to those skilled in the art, including but not limited to plasmid vectors, viral vectors, etc. The vector can also contain a variety of regulatory sequences for regulating expression. "Regulatory sequence" and "regulatory element" are used interchangeably herein and refer to nucleotide sequences located upstream (5' non-coding sequence), in the middle or downstream (3' non-coding sequence) of a coding sequence and affecting the transcription, RNA processing or stability or translation of the relevant coding sequence. Regulatory sequences can include but are not limited to promoter sequences, transcription start sequences, enhancer sequences, selection elements and reporter genes, etc. The regulatory sequences can be from different sources, or from the same source but arranged in a manner different from that usually naturally occurring. In addition, the vector can also contain a replication initiation site.
[0071] "Introducing" a nucleic acid molecule (e.g., a plasmid, a linear nucleic acid fragment, RNA, etc.) or a protein into an organism refers to transforming an organism cell with the nucleic acid or protein so that the nucleic acid or protein can function in the cell. "Transformation" as used in the present invention includes stable transformation and transient transformation.
[0072] The terms sequence "identity", "identity" or "homology" as used herein have their art-recognized meanings, and the percentage of sequence identity between two nucleic acid or polypeptide molecules or regions can be calculated using published techniques. Sequence identity can be measured along the entire length of a polynucleotide or polypeptide or along a region of the molecule (see, e.g., Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part I, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991). Although there are many methods for measuring the identity between two polynucleotides or polypeptides, the term "identity" is well known to those skilled in the art to apply conservative amino acid substitutions in peptides or proteins, and can generally be made without changing the biological activity of the resulting molecule. In general, those skilled in the art recognize that single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter the biological activity (see, e.g., Watson et al., Molecular Biology of the Gene, 4 th Edition, 1987, The Benjamin / Cummings Pub.co., p. 224).
[0073] The term "complementarity" as used herein refers to the ability of a nucleic acid sequence to form one or more hydrogen bonds with another nucleic acid sequence by means of traditional Watson-Crick or other non-traditional types. The percentage of complementarity represents the percentage of residues in a nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with another nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 are complementary, then the percentage of complementarity is 50%, 60%, 70%, 80%, 90% and 100%). "Complete complementarity" means that all consecutive residues of a nucleic acid sequence form hydrogen bonds with the same number of consecutive residues in another nucleic acid sequence. As used herein, "substantially complementary" refers to a degree of complementarity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50 or more nucleotides, or to two nucleic acids that hybridize under stringent conditions.
[0074] The term "stringent conditions" used herein in connection with hybridization refers to conditions in which a nucleic acid having complementarity with a target sequence primarily hybridizes with the target sequence and does not substantially hybridize to non-target sequences. Stringent conditions are generally sequence-dependent and depend on many factors. In general, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes to its target sequence. Non-limiting examples of stringent conditions are described in Tijssen, 1993, Laboratory Techniques in Biochemistry and Molecular Biology-Hybridization With Nucleic Acid Probes), Section I, Chapter II, "Overview of principles of hybridization and the strategy of nucleic acid probe assay", Elsevier, New York.
[0075] The term "hybridization" as used herein refers to a reaction in which one or more polynucleotide reactions form a complex that is stabilized via hydrogen bonding of bases between the nucleotide residues. Hydrogen bonding can occur by means of Watson-Crick base pairing, Hoogstein binding or in any other sequence-specific manner. The complex may include two chains forming a duplex, three or more chains forming a multi-chain complex, a single self-hybridizing chain, or any combination of these. Hybridization reactions can constitute a step in a more extensive process (such as the beginning of PCR or the cutting of polynucleotides via an enzyme). A sequence that can hybridize with a given sequence is referred to as the "complement" of the given sequence.
[0076] Cas12b protein
[0077] In the present invention, the "biological activity" of the Cas12b protein refers to the activity of the protein binding to a single-stranded guide RNA, endonuclease activity (including single-stranded cleavage activity and double-stranded cleavage activity), and / or the activity of binding to and cutting a specific site of a target sequence under the guidance of a guide RNA (gRNA), but is not limited thereto.
[0078] The inventors found that the NiCas12b protein with an amino acid sequence such as SEQ ID NO: 1 exhibited high editing activity when used in conjunction with the corresponding sgRNA. Therefore, the NiCas12b protein can be used to prepare a gene editing system.
[0079] Derivatized Protein
[0080] The protein can be derivatized, for example, by being connected to another molecule (e.g., another protein or polypeptide or a label). Typically, the derivatization of the protein will not adversely affect the desired activity of the protein (e.g., activity bound to a single-stranded guide RNA, endonuclease activity, activity bound to and cut with a specific site of a target sequence under the guidance of a guide RNA). Therefore, the NiCas12b protein of the present invention is also intended to include such derivatized forms. For example, the NiCas12b protein of the present invention can be functionally connected (by chemical coupling, gene fusion, non-covalent connection or other means) to one or more other molecular parts, such as another protein or polypeptide, a detectable label, a pharmaceutical agent, etc.
[0081] In particular, the Cas12b protein can be connected to other functional units. For example, it can be connected to a nuclear localization signal (NLS) sequence to improve the ability of the protein of the present invention to enter the nucleus. For example, it can be connected to a targeting moiety so that the Cas12b protein has targeting. For example, it can be connected to a detectable marker so that the Cas12b protein is detected. For example, it can be connected to an epitope tag so that the expression, detection, tracing and / or purification of the Cas12b protein is facilitated.
[0082] It is understood that in addition to the Cas12b protein itself, the Cas12b protein can also be combined with other substances such as other proteins and / or labelable tags to impart other functionalities.
[0083] Fusion protein containing Cas12b protein fragment
[0084] As mentioned above, the NiCas12b protein is difficult to effectively package into a special delivery system (such as adeno-associated virus) due to the excessive number of bases in its encoding gene. To solve this problem, the inventors attempted to truncate the NiCas12b protein into two protein fragments, namely, the NiCas12b-N terminus including the 1st-756th amino acid sequence of the NiCas12b protein and the NiCas12b-C terminus including the 757th-1439th amino acid sequence of the NiCas12b protein, and fused them with the N-terminus (intein-N, SEQ ID NO: 11) and C-terminus (intein-C, SEQ ID NO: 12) of the intein from Nostoc punctiforme (Npu DnaE for short), thereby obtaining two fusion proteins (referred to as NiCas12b-N-terminal fusion protein and NiCas12b-C-terminal fusion protein), which can be packaged into AAV viruses respectively. After the AAV virus is transduced into cells, it can be expressed in cells, mice, etc. and form a complete NiCas12b protein by means of the action of intein, thereby playing a gene editing role in the presence of corresponding sgRNA.
[0085] Therefore, in a first aspect of the present invention, a fusion protein is provided, comprising:
[0086] a) the NiCas12b protein N-terminus and the intein N-terminus whose amino acid sequence is represented by positions 1-756 of SEQ ID NO: 1; or
[0087] b) The NiCas12b protein C-terminus, and the peptide C-terminus, whose amino acid sequence is represented by positions 757-1439 of SEQ ID NO: 1.
[0088] In the context of the present invention, the fusion protein in a) above is referred to as “NiCas12b-N-terminal fusion protein” or “NiCas12b-756N-terminal fusion protein”, and the fusion protein in b) above is referred to as “NiCas12b-C-terminal fusion protein” or “NiCas12b-757C-terminal fusion protein”.
[0089] The term "intein" refers to an internal protein element that self-excises from its host protein and catalyzes the connection of flanking sequences (exteins) through peptide bonds. Intein excision does not require post-translational processing by auxiliary enzymes or cofactors. This self-cleavage process is called "protein splicing", which is similar to the splicing of RNA introns from pre-mRNA (Perler F et al., Nucl Acids Res. 22: 1125-1127 (1994)). Splitting intein contains N-terminus (intein-N) and C-terminus (intein-C), which are connected to N-extein and C-extein, respectively, and become N-protein and C-protein after translation. After the intein helps N-protein and C-protein to complete the connection, it will eventually self-cleave from the mature protein to ensure the function of the complete protein. Currently, split inteins have been identified in a variety of cyanobacteria and archaea.
[0090] In a specific embodiment, the intein can be a broken intein, such as Npu DnaE intein from Nostoc punctiforme, Syn DnaE intein from Synechocystis sp. PCC6803, etc., but not limited thereto. These inteins can promote the seamless assembly of the N-terminus and C-terminus of NiCas12b protein into complete proteins in vivo and in vitro.
[0091] In a preferred embodiment, the intein is Npu DnaE intein, the amino acid sequence at the N-terminus thereof is represented by SEQ ID NO:11, and the amino acid sequence at the C-terminus thereof is represented by SEQ ID NO:12.
[0092] In a further preferred embodiment, the amino acid sequence of the fusion protein in a) is shown as SEQ ID NO:3.
[0093] In a further preferred embodiment, the amino acid sequence of the fusion protein in b) is shown as SEQ ID NO:4.
[0094] In a second aspect, the present invention provides a conjugate comprising:
[0095] a) the fusion protein described in the first aspect;
[0096] b) a detectable label and / or an additional protein or polypeptide; and
[0097] c) optionally a linker for connecting the fusion protein to the detectable label or the additional protein or polypeptide.
[0098] In a specific embodiment, the additional protein or polypeptide is selected from one or more of an epitope tag, a reporter protein or a nuclear localization signal (NLS) sequence, a cytosine deaminase (CBE), adenine deaminase (ABE), a cytosine methylase DNMT3A and MQ1, a cytosine demethylase Tet1, a transcriptional activator protein VP64, p65 and RTA, a transcriptional repressor protein KRAB, a histone acetylase p300, a histone deacetylase LSD1, and an endonuclease FokI.
[0099] Detectable labels are well known to those skilled in the art, and examples include fluorescent dyes such as fluorescein isothiocyanate (FITC) or DAPI.
[0100] The NiCas12b-N-terminal fusion protein or NiCas12b-C-terminal fusion protein of the present invention can be coupled, conjugated or fused to the detectable marker or the other protein or polypeptide through a linker, or can be directly connected to the detectable marker or the other protein or polypeptide without a linker. Linkers are well known in the art, and examples thereof include, but are not limited to, linkers comprising 1-50 amino acids (such as Glu or Ser) or amino acid derivatives (such as Ahx, β-Ala, GABA or Ava), or PEG, etc.
[0101] Epitope tags are well known to those skilled in the art, examples of which include but are not limited to His, V5, FLAG, HA, Myc, VSV-G, Trx, etc., and those skilled in the art know how to select a suitable epitope tag according to the desired purpose (e.g., purification, detection or tracing).
[0102] Reporter proteins are well known to those skilled in the art, and examples thereof include but are not limited to GST, HRP, CAT, GFP, HcRed, DsRed, CFP, YFP, BFP, etc.
[0103] Single-stranded guide RNA
[0104] In a third aspect, the present invention provides a single-stranded guide RNA, wherein the single-stranded guide RNA comprises a scaffold sequence and a CRISPR spacer sequence from the 5' end to the 3' end, wherein the scaffold sequence is:
[0105] a) a scaffold sequence as shown in SEQ ID NO: 7 or SEQ ID NO: 9; or
[0106] b) a sequence modified based on the sequence shown in SEQ ID NO: 7 or SEQ ID NO: 9 and retaining its biological activity.
[0107] The wild-type NiCas12b-sgRNA scaffold sequence (SEQ ID NO: 7) is composed of a full-length direct repeat sequence and a full-length tracrRNA on the bacterial genome. In order to further optimize the sgRNA scaffold sequence, the inventors obtained a schematic diagram of the sgRNA secondary structure through RNAfold website analysis. According to the secondary structure, the inventors constructed a variety of sgRNA variants, among which the truncated body 3 (abbreviated as V3) with appropriate truncation of the repeat region and the anti-repeat region was shown to improve the editing efficiency of NiCas12b. The sequence of the truncated body 3 is shown in SEQ ID NO: 9.
[0108] In a specific embodiment, the modification is one or more of base phosphorylation, base sulfurization, base methylation, base hydroxylation, sequence shortening and sequence lengthening.
[0109] In a further specific embodiment, the shortening of the sequence and the lengthening of the sequence comprise the deletion or addition of one, two, three, four, five, six, seven, eight, nine or ten bases relative to the base sequence.
[0110] In another specific embodiment, the CRISPR spacer sequence is a sequence with a length of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides and is capable of complementary pairing with the target sequence.
[0111] In a preferred embodiment, the CRISPR spacer sequence is a sequence with a length of 24 nucleotides and capable of complementary pairing with the target sequence.
[0112] In a further embodiment, the single-stranded guide RNA further comprises a terminator at the 3' end of the scaffold sequence. As an example, the terminator can be a terminator consisting of multiple, such as at least six (eg, seven or eight) Us.
[0113] The single-stranded guide RNA can bind to the above-mentioned Cas12 protein, conjugate or fusion protein to form a complex, which can recognize the corresponding PAM (e.g., 5'-TTN) and thereby bind to the target sequence, thereby achieving shearing or gene editing of the target sequence.
[0114] Encoding nucleic acid and vector
[0115] In a fourth aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein of the first aspect or the conjugate of the second aspect.
[0116] In a specific embodiment, the isolated nucleic acid molecule comprises the nucleic acid sequence shown in SEQ ID NO: 5 or 6 or a degenerate sequence thereof.
[0117] As mentioned above, when the nucleic acid molecule encoding NiCas12b-N-terminal fusion protein or its conjugate of the present invention and the nucleic acid molecule encoding NiCas12b-C-terminal fusion protein or its conjugate are packaged separately, they can be expressed in cells, mice, etc., and can form a complete NiCas12b protein under the mediation of intein. It is understood that after the complete NiCas12b protein is formed, the protein can still perform corresponding functions with the single-stranded guide RNA described above, such as gene editing.
[0118] In the fifth aspect, the isolated nucleic acid molecule comprises a nucleic acid sequence encoding the single-stranded guide RNA of the third aspect.
[0119] In a specific embodiment, the isolated nucleic acid molecule comprises the nucleic acid sequence shown in SEQ ID NO:8 or SEQ ID NO:10.
[0120] The above description of single-stranded guide RNA is applicable to this aspect of the present invention and will not be repeated here.
[0121] In another specific embodiment, the isolated nucleic acid molecule further comprises a nucleic acid sequence encoding a NiCas12b protein or a conjugate or fusion protein thereof whose amino acid sequence is shown in SEQ ID NO: 1.
[0122] In one embodiment, the conjugate of the NiCas12b protein comprises: a NiCas12b protein; a detectable label, or a combination of a detectable label and another protein or polypeptide; and an optional linker for connecting the NiCas12b protein to the detectable label;
[0123] Wherein, the fusion protein of the NiCas12b protein comprises: NiCas12b protein; other proteins and polypeptides; and optionally a linker for connecting the NiCas12b protein with the other proteins and polypeptides.
[0124] In a specific embodiment, the additional protein or polypeptide is selected from one or more of an epitope tag, a reporter protein or a nuclear localization signal sequence, a cytosine deaminase, adenine deaminase, a cytosine methylase DNMT3A and MQ1, a cytosine demethylase Tet1, a transcriptional activator protein VP64, p65 and RTA, a transcriptional repressor protein KRAB, a histone acetylase p300, a histone deacetylase LSD1, and an endonuclease FokI.
[0125] In a specific embodiment, the isolated nucleic acid molecule further comprises the nucleic acid sequence shown in SEQ ID NO: 2 or a degenerate sequence thereof.
[0126] The description above of the conjugate, fusion protein, detectable marker, other protein or polypeptide, epitope tag, reporter protein, connector, etc. of NiCas12b protein is also applicable to this aspect of the present invention, so it is not repeated here.
[0127] In addition, the isolated nucleic acid molecule of the present invention can express Cas12b protein or its conjugate or fusion protein, and single-stranded guide RNA individually / separately, or can express the expression product as a whole, and the expression method selected depends on the specific circumstances.
[0128] Furthermore, the isolated nucleic acid molecule of the present invention preferably expresses NiCas12b-N-terminal fusion protein or its conjugate, NiCas12b-C-terminal fusion protein or its conjugate in different expression vectors, thereby achieving viral packaging.
[0129] Furthermore, the expression product has the corresponding effects and / or functions described above, which will not be repeated here for the sake of brevity.
[0130] In a sixth aspect, the present invention provides a vector comprising a nucleic acid sequence encoding the fusion protein of the first aspect or the conjugate of the second aspect.
[0131] In a specific embodiment, the vector comprises the nucleic acid sequence shown in SEQ ID NO: 5 or 6 or a degenerate sequence thereof.
[0132] In another specific embodiment, the vector can be an expression vector, such as a plasmid vector such as a pUC19 vector, an episome vector, a pAAV2_ITR vector, a retroviral vector, a lentiviral vector, an adenoviral vector or an adeno-associated viral vector.
[0133] In yet another specific embodiment, the vector further comprises a nucleic acid sequence encoding the single-stranded guide RNA described in the third aspect.
[0134] In one embodiment, the nucleic acid sequence encoding the NiCas12b-N-terminal fusion protein can be in a vector with the nucleic acid sequence encoding the single-stranded guide RNA and expressed under the action of different promoters.
[0135] In another embodiment, the nucleic acid sequence encoding the NiCas12b-C-terminal fusion protein can be in the same vector with the nucleic acid sequence encoding the single-stranded guide RNA and expressed under the action of different promoters.
[0136] In a further specific embodiment, the vector further comprises the nucleic acid sequence shown in SEQ ID NO:8 or SEQ ID NO:10.
[0137] The above description of single-stranded guide RNA is applicable to this aspect of the present invention and will not be repeated here.
[0138] In a seventh aspect, the present invention provides a vector comprising a nucleic acid sequence encoding the single-stranded guide RNA of the third aspect.
[0139] In a specific embodiment, the vector comprises the nucleic acid sequence shown in SEQ ID NO:8 or SEQ ID NO:10.
[0140] The above description of single-stranded guide RNA is applicable to this aspect of the present invention and will not be repeated here.
[0141] In another specific embodiment, the isolated nucleic acid molecule further comprises a nucleic acid sequence encoding a NiCas12b protein or a conjugate or fusion protein thereof whose amino acid sequence is shown in SEQ ID NO: 1.
[0142] In a specific embodiment, the conjugate of the NiCas12b protein comprises: a NiCas12b protein; a detectable label, or a combination of a detectable label and another protein or polypeptide; and an optional linker for connecting the NiCas12b protein to the detectable label.
[0143] In a specific embodiment, the fusion protein of the NiCas12b protein comprises: NiCas12b protein; additional proteins and polypeptides; and optionally a linker for connecting the NiCas12b protein to the additional proteins and polypeptides.
[0144] In a specific embodiment, the additional protein or polypeptide is selected from one or more of an epitope tag, a reporter protein or a nuclear localization signal (NLS) sequence, a cytosine deaminase (CBE), adenine deaminase (ABE), a cytosine methylase DNMT3A and MQ1, a cytosine demethylase Tet1, a transcriptional activator protein VP64, p65 and RTA, a transcriptional repressor protein KRAB, a histone acetylase p300, a histone deacetylase LSD1, and an endonuclease FokI.
[0145] In a specific embodiment, the isolated nucleic acid molecule further comprises the nucleic acid sequence shown in SEQ ID NO: 2 or a degenerate sequence thereof.
[0146] The descriptions of NiCas12b protein, NiCas12b-N-terminal fusion protein, NiCas12b-C-terminal fusion protein, conjugate, fusion protein, detectable marker, additional protein or polypeptide, epitope tag, reporter protein, linker, etc. described above are also applicable to this aspect of the present invention, so they are not repeated here.
[0147] A variety of vectors of the present invention, such as two vectors, can be transfected into cells. For example, for NiCas12 protein and sgRNA, two vectors can be used, one of which expresses NiCas12b protein or its conjugate or fusion protein, and another vector expresses single-stranded guide RNA, and the expressed NiCas12b protein, its conjugate or fusion protein is compounded with the expressed single-stranded guide RNA to form a complex, and the corresponding functions are performed here, such as gene editing. For example, for NiCas12b-N-terminal fusion protein, NiCas12b-C-terminal fusion protein and sgRNA, two vectors can be used, one of which expresses NiCas12b-N-terminal fusion protein or its conjugate, another vector expresses NiCas12b-C-terminal fusion protein or its conjugate and single-stranded guide RNA, or one vector expresses NiCas12b-N-terminal fusion protein or its conjugate and sgRNA, and another vector expresses NiCas12b-C-terminal fusion protein or its conjugate; three vectors can also be used to express NiCas12b-N-terminal fusion protein, NiCas12b-C-terminal fusion protein and sgRNA respectively. The expressed NiCas12b-N-terminal fusion protein or its conjugate and the NiCas12b-C-terminal fusion protein or its conjugate will be reconnected under the mediation of their respective intein to form a complete NiCas12b protein or its conjugate, which will form a complex with the expressed single-stranded guide RNA and perform corresponding functions therein, such as gene editing.
[0148] Of course, the nucleic acid sequence encoding NiCas12b protein or its conjugate or fusion protein and the nucleic acid sequence encoding single-stranded guide RNA can also be cloned into a vector so that the vector is transfected into the cell and then expresses the NiCas12b protein or its conjugate or fusion protein and the single-stranded guide RNA, and performs the corresponding functions, such as gene editing. However, considering that the nucleic acid sequence encoding NiCas12b protein or its conjugate or fusion protein is too large, it is not preferred.
[0149] CRISPR / Cas12b gene editing system
[0150] In an eighth aspect, the present invention provides a CRISPR / Cas12b gene editing system comprising:
[0151] 1) A protein component comprising:
[0152] a) the fusion protein described in a) of the first aspect or the corresponding conjugate described in the second aspect, and the fusion protein described in b) of the first aspect or the corresponding conjugate described in the second aspect; or
[0153] b) a NiCas12b protein having an amino acid sequence as shown in SEQ ID NO: 1, or a conjugate or fusion protein thereof; and
[0154] 2) the single-stranded guide RNA described in the third aspect;
[0155] Furthermore, the protein component and the single-stranded guide RNA bind to each other to form a complex;
[0156] Wherein, the conjugate of the NiCas12b protein comprises: NiCas12b protein; a detectable marker, or a combination of a detectable marker and another protein or polypeptide; and an optional linker for connecting the fusion protein to the detectable marker or the other protein or polypeptide;
[0157] Wherein, the fusion protein of the NiCas12b protein comprises: NiCas12b protein; other proteins and polypeptides; and optionally a linker for connecting the fusion protein with the other proteins and polypeptides.
[0158] It can be understood that in the CRISPR / Cas12b gene editing system of the present invention, the protein portion can be a directly expressed complete NiCas12b protein or its conjugate or fusion protein, or it can be an expressed NiCas12b-N-terminal fusion protein or its conjugate and NiCas12b-C-terminal fusion protein or its conjugate, which form a complete NiCas12b protein or its conjugate under the mediation of the intein.
[0159] In a specific embodiment, the additional protein or polypeptide is selected from one or more of an epitope tag, a reporter protein or a nuclear localization signal sequence, a cytosine deaminase, adenine deaminase, a cytosine methylase DNMT3A and MQ1, a cytosine demethylase Tet1, a transcriptional activator protein VP64, p65 and RTA, a transcriptional repressor protein KRAB, a histone acetylase p300, a histone deacetylase LSD1, and an endonuclease FokI.
[0160] The descriptions above of NiCas12b protein or its conjugate or fusion protein, NiCas12b-N-terminal fusion protein or its conjugate, NiCas12b-C-terminal fusion protein or its conjugate, detectable marker, additional protein or polypeptide, epitope tag, reporter protein, linker, etc. are also applicable to this aspect of the present invention, so they are not repeated here.
[0161] The CRISPR / Cas12b gene editing system of the present invention can be directly composed of the NiCas12b protein of the present invention, its conjugate or fusion protein and single-stranded guide RNA, or it can be composed of the expression product obtained by expressing the isolated nucleic acid molecule or vector described herein. The CRISPR / Cas12b gene editing system of the present invention realizes the recognition, positioning, cutting and gene editing of the target sequence through the NiCas12b protein and single-stranded guide RNA contained therein.
[0162] The CRISPR / Cas12b gene editing system of the present invention can accurately locate the target sequence. The so-called "precise positioning" has two meanings: the first meaning is that the CRISPR / Cas12b gene editing system of the present invention itself can recognize and bind to the target sequence, and the second meaning is that the CRISPR / Cas12b gene editing system of the present invention can bring other proteins fused with the NiCas12b protein or proteins that specifically recognize the sgRNA to the location of the target sequence.
[0163] The CRISPR / Cas12b gene editing system of the present invention has a low tolerance for non-target sequences. In this article, the so-called "low tolerance" means that the CRISPR / Cas12b gene editing system of the present invention is substantially unable or completely unable to recognize and bind to non-target sequences, or substantially unable or completely unable to bring other proteins fused to the Cas12b protein or proteins that specifically recognize the sgRNA to the position of non-target sequences.
[0164] Gene Editing Methods
[0165] In a ninth aspect, the present invention provides a method for gene editing a target sequence in a cell or in vitro environment, the method comprising: contacting any one of the following (1) to (7) with the target sequence in the cell or in vitro environment:
[0166] (1) the fusion protein described in a) of the first aspect or the corresponding conjugate described in the second aspect, the fusion protein described in b) of the first aspect or the corresponding conjugate described in the second aspect, and the single-stranded guide RNA described in the third aspect;
[0167] (2) the isolated nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein described in a) of the first aspect or the corresponding conjugate described in the second aspect as described in the fourth aspect, the isolated nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein described in b) of the first aspect or the corresponding conjugate described in the second aspect as described in the fourth aspect, and the isolated nucleic acid molecule encoding the nucleic acid sequence of the single-stranded guide RNA described in the third aspect;
[0168] (3) The isolated nucleic acid molecule of the fifth aspect comprising a nucleic acid sequence encoding the single-stranded guide RNA of the third aspect of the present invention and the NiCas12b protein or its conjugate or fusion protein whose amino acid sequence is shown in SEQ ID NO: 1;
[0169] (4) The vector according to the sixth aspect comprising a nucleic acid sequence encoding the fusion protein described in a) of the first aspect or the corresponding conjugate described in the second aspect, the vector according to the sixth aspect comprising a nucleic acid sequence encoding the fusion protein described in b) of the first aspect or the corresponding conjugate described in the second aspect and a nucleic acid sequence encoding the single-stranded guide RNA described in the third aspect;
[0170] (5) The vector according to the sixth aspect comprising a nucleic acid sequence encoding the fusion protein described in b) of the first aspect or the corresponding conjugate described in the second aspect, and the vector according to the sixth aspect comprising a nucleic acid sequence encoding the fusion protein described in a) of the first aspect or the corresponding conjugate described in the second aspect and a nucleic acid sequence encoding the single-stranded guide RNA described in the third aspect;
[0171] (6) The vector of the seventh aspect comprising a nucleic acid sequence encoding the single-stranded guide RNA of the third aspect of the present invention and the NiCas12b protein or its conjugate or fusion protein as shown in SEQ ID NO: 1;
[0172] (7) The CRISPR / Cas12b gene editing system described in the eighth aspect;
[0173] Wherein, the conjugate or the fusion protein recognizes a protospacer adjacent sequence (PAM) located at the 5' end of the target sequence and having the sequence 5'-TTN.
[0174] In a specific embodiment, the cell is a non-plant cell, such as a prokaryotic cell or an animal cell, such as a mammalian cell such as a human cell.
[0175] In another specific embodiment, the gene editing includes one or more of gene knockout, site-specific base change, site-specific insertion, regulation of gene transcription level, DNA methylation regulation, DNA acetylation modification, histone acetylation modification, single base conversion, and chromatin imaging tracking of the target sequence. For example, the single base conversion includes the conversion of adenine to guanine, cytosine to thymine, or cytosine to uracil.
[0176] In yet another specific embodiment, in the method, the guide sequence of the single-stranded guide RNA forms a complete base complementary pairing structure with the target sequence, and forms an incomplete base complementary pairing structure with a non-target sequence.
[0177] Herein, the incomplete base complementary pairing structure refers to a structure including a portion of base complementary pairing and a portion of non-base complementary pairing, wherein the non-base complementary pairing includes, for example, base mismatch and / or base bulge.
[0178] In a further specific embodiment, the incomplete base complementary pairing structure comprises one or more, for example, two or more base mismatches.
[0179] Thus, the NiCas12b protein of the present invention can cut the target site on the target sequence, and under the cutting action of the NiCas12b protein, a double-strand break occurs in the target sequence. Further, when the method is performed in a cell, the cut target sequence can be repaired by non-homologous end joining repair or homologous recombination repair pathways in the cell, thereby achieving gene editing of the target sequence.
[0180] The CRISPR / Cas12b gene editing system of the present invention and the gene editing method using the gene editing system have high editing activity, low off-target rate and high specificity. In the research results for the CRISPR / NiCas12b gene editing system, no obvious mismatch phenomenon was found in the first 21bp single base mismatch, indicating that the CRISPR / NiCas12b gene editing system has extremely high requirements for the complete pairing between gRNA and the target sequence, has a lower fault tolerance rate and a higher safety of practical application, and can be widely used in cells or gene editing in an in vitro environment.
[0181] Methods for expressing NiCas12b protein
[0182] In a tenth aspect, the present invention provides a method for expressing a NiCas12b protein having an amino acid sequence as shown in SEQ ID NO: 1 in a cell or in vitro environment, comprising using the following (1) or (2):
[0183] (1) The isolated nucleic acid molecule of the fourth aspect comprising a nucleic acid sequence encoding the fusion protein of the first aspect a) or the corresponding conjugate of the second aspect, and the isolated nucleic acid molecule of the fourth aspect comprising a nucleic acid sequence encoding the fusion protein of the first aspect b) or the corresponding conjugate of the second aspect;
[0184] (2) The vector of the sixth aspect comprising a nucleic acid sequence encoding the fusion protein described in a) of the first aspect or the corresponding conjugate described in the second aspect, and the vector of the sixth aspect comprising a nucleic acid sequence encoding the fusion protein described in b) of the first aspect or the corresponding conjugate described in the second aspect.
[0185] cell
[0186] In the eleventh aspect, the present invention provides a cell, comprising: the isolated nucleic acid molecule described in the fourth aspect or the fifth aspect, or the vector described in the sixth aspect or the seventh aspect.
[0187] As an example, the cell may be a non-plant cell, such as a prokaryotic cell or an animal cell. As for the animal cell, as an example, it may be a mammalian cell such as a human cell.
[0188] Reagent test kit
[0189] In a twelfth aspect, the present invention provides a kit for gene editing a target sequence in a cell or in vitro environment, comprising:
[0190] a) Any one selected from the following (1) to (7):
[0191] (1) the fusion protein described in a) of the first aspect or the corresponding conjugate described in the second aspect, the fusion protein described in b) of the first aspect or the corresponding conjugate described in the second aspect, and the single-stranded guide RNA described in the third aspect;
[0192] (2) the isolated nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein described in a) of the first aspect or the corresponding conjugate described in the second aspect as described in the fourth aspect, the isolated nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein described in b) of the first aspect or the corresponding conjugate described in the second aspect as described in the fourth aspect, and the isolated nucleic acid molecule encoding the nucleic acid sequence of the single-stranded guide RNA described in the third aspect;
[0193] (3) The isolated nucleic acid molecule of the fifth aspect comprising a nucleic acid sequence encoding the single-stranded guide RNA of the third aspect of the present invention and the NiCas12b protein or its conjugate or fusion protein whose amino acid sequence is shown in SEQ ID NO: 1;
[0194] (4) The vector according to the sixth aspect comprising a nucleic acid sequence encoding the fusion protein described in a) of the first aspect or the corresponding conjugate described in the second aspect, the vector according to the sixth aspect comprising a nucleic acid sequence encoding the fusion protein described in b) of the first aspect or the corresponding conjugate described in the second aspect and a nucleic acid sequence encoding the single-stranded guide RNA described in the third aspect;
[0195] (5) The vector according to the sixth aspect comprising a nucleic acid sequence encoding the fusion protein described in b) of the first aspect or the corresponding conjugate described in the second aspect, and the vector according to the sixth aspect comprising a nucleic acid sequence encoding the fusion protein described in a) of the first aspect or the corresponding conjugate described in the second aspect and a nucleic acid sequence encoding the single-stranded guide RNA described in the third aspect;
[0196] (6) The vector of the seventh aspect comprising a nucleic acid sequence encoding the single-stranded guide RNA of the third aspect of the present invention and the NiCas12b protein or its conjugate or fusion protein as shown in SEQ ID NO: 1;
[0197] (7) The CRISPR / Cas12b gene editing system described in the eighth aspect;
[0198] as well as
[0199] b) Instructions for performing gene editing on the target sequence in cells or in vitro.
[0200] Of course, those skilled in the art will appreciate that the kit of the present invention may also include other reagents that are helpful for gene editing.
[0201] Brief description of the sequence involved in the present invention
[0202] SEQ ID NO: 1: NiCas12b protein sequence
[0203] SEQ ID NO: 2: Coding sequence of NiCas12b protein sequence
[0204] SEQ ID NO:3: Sequence of NiCas12b-756 N-terminal protein fragment
[0205] SEQ ID NO:4: Sequence of NiCas12b-757 C-terminal protein fragment
[0206] SEQ ID NO:5: Coding sequence of NiCas12b-756 N-terminal protein fragment
[0207] SEQ ID NO:6: Coding sequence of NiCas12b-757 C-terminal protein fragment
[0208] SEQ ID NO:7: Scaffold sequence of single-stranded guide RNA
[0209] SEQ ID NO:8: DNA sequence of the scaffold sequence of the single-stranded guide RNA
[0210] SEQ ID NO:9: Scaffold sequence of single-stranded guide RNA variant V3
[0211] SEQ ID NO: 10: DNA sequence of the scaffold sequence of the single-stranded guide RNA variant V3
[0212] SEQ ID NO: 11: Sequence of the N-terminal protein fragment of Npu DnaE intein
[0213] SEQ ID NO: 12: Sequence of the C-terminal protein fragment of Npu DnaE intein
[0214] SEQ ID NO: 13: DNA sequence of the scaffold sequence of single-stranded guide RNA variant V1
[0215] SEQ ID NO: 14: DNA sequence of the scaffold sequence of the single-stranded guide RNA variant V2
[0216] SEQ ID NO: 15: DNA sequence of the scaffold sequence of the single-stranded guide RNA variant V4
[0217] SEQ ID NO: 16: Coding sequence of NiCas12b-540 N-terminal protein fragment
[0218] SEQ ID NO: 17: Coding sequence of NiCas12b-631 N-terminal protein fragment
[0219] SEQ ID NO: 18: Coding sequence of NiCas12b-541 C-terminal protein fragment
[0220] SEQ ID NO: 19: Example of coding sequence of NiCas12b-632 C-terminal protein fragment
[0221] The present invention is now described with reference to the following examples which are intended to illustrate but not to limit the present invention. It is understood by those skilled in the art that the examples are provided here only for the purpose of describing the present invention in detail and are not intended to limit the scope of the present invention.
[0222] Unless otherwise specified, the experiments and methods described in the examples were performed in accordance with conventional methods well known in the art and described in the references. In addition, for those examples where specific conditions are not specified, conventional conditions or conditions recommended by the manufacturer were used. The reagents or instruments used where the manufacturer is not specified are all conventional products that can be obtained commercially.
[0223] Example 1
[0224] (1) Construction of plasmid pAAV-NiCas12b-puro
[0225] The amino acid sequence of NiCas12b protein was downloaded from NCBI (SEQ ID NO: 1, whose gene accession number is MCP9456315.1).
[0226] The sequence encoding the NiCas12b protein was codon optimized to obtain a gene sequence (SEQ ID NO: 2) of the NiCas12b protein highly expressed in human cells.
[0227] The gene sequence (SEQ ID NO: 2) was synthesized and constructed into the pAAV-CMV-Hsp2Cas9 plasmid (Addgene platform, catalog #192126) backbone (i.e., between the pCMV promoter and the SV40 terminator, and the Cj gRNA scaffold element on the backbone was deleted) to obtain the plasmid pAAV-NiCas12b.
[0228] The pAAV-NiCas12b-puro plasmid can be constructed by cloning the puro and P2A elements of epiCRISPRe (Addgene platform, catalog #135962) before the stop codon of the NiCas12b coding sequence of the plasmid pAAV-NiCas12b.
[0229] Table 1: Primers used to construct pAAV-NiCas12b and pAAV-NiCas12b-puro
[0230] Primer name sequence pAAV1-F CCATATATGGAGTTCCGCGTTAC pAAV1-R CACCTTTCTCTTCTTCTTGGGGCT pAAV2-F TAGCTCGAGCTCGATGAGTTTG pAAV2-R CGGAACTCCATATATGGGCTATG puro-F CAAGAAGAAGAGAAAGGTGGCTAGCGGCAGCGGCGCCAC puro-R TCATCGAGCTCGAGCTAGGCACCGGGCTTGCGGGTCAT pAAV-notracr-R GGACGCTTCGACCTTGCGCTTTTTCTTC pAAV-notracr-F AGCCCCAAGAAGAAGAGAAAGGT
[0231] The PCR reaction system is as follows:
[0232]
[0233] The PCR run procedure is as follows:
[0234]
[0235] The PCR product was electrophoresed on a 1% agarose gel at 120 V for 30 min, and the target DNA fragment was purified using a gel recovery kit according to the manufacturer's steps. TM The DNA concentration was determined using a Lite spectrophotometer (Thermo Scientific).
[0236] The homologous recombination kit ClonExpress Ultra One Step Cloning Kit (purchased from Nanjing Novogene Biotechnology Co., Ltd.) was used to recombinantly connect the fragments after PCR, and the reaction was carried out at 50°C for 5 minutes.
[0237] The ligation product was added to Escherichia coli DH5α competent cells (purchased from Shanghai Weidi Biotechnology Co., Ltd.), incubated on ice for 30 min, heat shocked at 42°C for 1 min, incubated on ice for 2 min, 900 μL LB medium was added, and cultured at 37°C for 1 hour to activate and recover the Escherichia coli DH5α competent cells.
[0238] The revived E. coli DH5α competent cells were spread on LB solid plates containing ampicillin resistance and cultured upside down in a 37° C. incubator. The obtained E. coli DH5α single clone was verified by Sanger sequencing.
[0239] The Escherichia coli DH5α clone with correct connection verified by sequencing was shaken to extract the plasmid, that is, the plasmid pAAV-NiCas12b-puro containing the nucleic acid sequence expressing NiCas12b protein was obtained and set aside.
[0240] (2) Construction of plasmid pUC19-NiCas12b-scaffold
[0241] The scaffold sequence (SEQ ID NO: 7) was constructed based on the direct repeat sequence (repeat) and tracrRNA sequence on the bacterial genome.
[0242] The above scaffold sequence was synthesized (and the hU6 promoter was synthesized before the scaffold sequence) and constructed on a linearized pUC19 (Addgene platform, catalog #50005) plasmid. The pUC19 vector was linearized using PCR, and the homologous recombination kit was used to react at 50°C for 5 minutes. The ligation product was added to the E. coli DH5α competent cells (purchased from Shanghai Weidi Biotechnology Co., Ltd.), incubated on ice for 30 minutes, heat-shocked at 42°C for 1 minute, incubated on ice for 2 minutes, and 900 μL LB medium was added. The cells were cultured at 37°C for 1 hour to activate and resuscitate the E. coli DH5α competent cells. The revived E. coli DH5α competent cells were spread on a solid LB plate containing ampicillin resistance and inverted in a 37°C incubator. The obtained E. coli DH5α monoclonal clone was verified by Sanger sequencing.
[0243] After completing sequencing verification, the pUC19-NiCas12b-scaffold plasmid was obtained.
[0244] Table 2: Primers used to construct pUC19-NiCas12b-scaffold
[0245] Primer name sequence M13R-F GTCATAGCTGTTTCCTGTGTGAA hU6-R AATCATGGGAAATAGGCCCTC Fragment.FOR GAGGGCCTATTTCCCATGATT Fragment.REV CAGGAAACAGCTATGACTTCCTGCGGCCGCAAAAAAAACG
[0246] (3) Preparation of linearized plasmid pUC19-NiCas12b-scaffold
[0247] The plasmid pUC19-NiCas12b-scaffold prepared in (2) was digested with BspQI restriction endonuclease (NEB, catalog number R0712S), and the digestion system was: 1 μg plasmid pUC19-NiCas12b-scaffold, 1 μL BspQI restriction endonuclease, 5 μL 10×CutSmart buffer (purchased from NEB), and water was added to 50 μL. The digestion system was reacted at 37° C. for 0.5-1 hour.
[0248] Then, the digested products were electrophoresed on 1% agarose gel at a voltage drop of 5 V / cm for 30 min.
[0249] The DNA fragments were cut from the agarose gel and recovered using a gel recovery kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., DP209) according to the manufacturer's instructions, and finally eluted with ultrapure water. The recovered linearized plasmid pUC19-NiCas12b-scaffold was purified by NanoDrop TM The DNA concentration was measured by Lite spectrophotometer (Thermo Scientific) and stored for later use or at -20°C for long-term storage.
[0250] (4) Preparation of sgRNA targeting plasmid based on pUC19-NiCas12b-scaffold
[0251] In order to test the effect of different Spacer lengths on NiCas12b efficiency, gRNAs containing 19bp-26bp Spacer were designed, and their sequences are shown in Table 3. Their target sites are all A3. For each gRNA sequence, the sticky end sequences corresponding to both sides of the linearized plasmid pUC19-NiCas12b-scaffold were added to the sense strand and antisense strand, and two oligonucleotide single-stranded DNAs were synthesized. The specific sequences of these two oligonucleotide single-stranded DNAs are also shown in Table 3 below.
[0252] Table 3: gRNA targeting A3 site and its DNA sequence
[0253]
[0254]
[0255] Note: The capital letters in the table represent the sticky end sequences corresponding to both sides of the linearized plasmid pUC19-NiCas12b-scaffold
[0256] The oligonucleotide single-stranded DNA was annealed to obtain double-stranded DNA. The annealing reaction system was: 1 μL 100 μM oligo-F, 1 μL 100 μM oligo-R, and 28 μL water. After the annealing system was shaken and mixed, it was placed in a PCR instrument to run the annealing program. The annealing program was: 95°C_5min, 85°C_1min, 75°C_1min, 65°C_1min, 55°C_1min, 45°C_1min, 35°C_1min, 25°C_1min, 4°C storage, and a cooling rate of 0.3°C / s. After annealing, the resulting product was connected to the linearized pUC19-NiCas12b-scaffold-sg plasmid by DNA ligase (purchased from NEB).
[0257] Take 1 μL of the obtained ligation product and add it to Escherichia coli DH5α competent cells (purchased from Shanghai Weidi Biotechnology Co., Ltd.), incubate on ice for 30 min, heat shock at 42°C for 1 min, incubate on ice for 2 min, add 900 μL LB medium, and culture at 37°C for 1 hour to activate and resuscitate the Escherichia coli DH5α competent cells.
[0258] The revived E. coli DH5α competent cells were spread on LB solid plates containing corresponding resistance and cultured inverted in a 37°C incubator. The obtained E. coli DH5α single clone was verified by Sanger sequencing.
[0259] The E. coli DH5α clone with correct connection verified by sequencing was shaken and the plasmid was extracted to obtain the plasmid pUC19-NiCas12b-scaffold-sg plasmid containing the target sgRNA sequence for expression, which was set aside.
[0260] (5) Co-transfection of HEK293T cell line with plasmid pAAV-NiCas12b-puro expressing NiCas12b protein and plasmid pUC19-NiCas12b-scaffold-sg expressing sgRNA
[0261] On day 0, according to the transfection requirements, HEK293T cells (GFP reporter system) containing the target sequence (TTGGGTGAGGGAGGAGAGATGCCCGGAGA) were plated in 48-well plates with a cell density of about 30% (if other well plates are used, the system can be scaled up or down in equal proportion).
[0262] On day 1, transfection was performed. The transfection process was as follows:
[0263] 500 ng of pAAV-NiCas12b-puro plasmid and 300 ng of pUC19-NiCas12b-scaffold-sg plasmid were added to 12.5 μL Opti-MEM medium (purchased from Gibco) and gently pipetted to mix. pUC19-NiCas12b-scaffold-sg containing sgRNAs of different Spacer lengths were co-transfected with pAAV-NiCas12b-puro.
[0264] Lipofectamine 2000 (purchased from Invitrogen) or polyethyleneimine (hereinafter referred to as PEI) (purchased from Polysciences) was flicked to mix, and 1.6 μL was drawn. 2000 or PEI was added to 12.5 μL Opti-MEM medium (purchased from Gibco), gently mixed, and allowed to stand at room temperature for 5 min.
[0265] The diluted transfection reagent and the diluted plasmid were mixed, gently pipetted to mix, and allowed to stand at room temperature for 20 minutes, and then added to the culture medium containing the HEK293T cells to be transfected. The cells were then placed in a 37°C, 5% CO2 incubator for further culture for 3 days, and then screened with puromycin (puro) for 5 days.
[0266] (6) Preparation of Next-Generation Sequencing Library
[0267] HEK293T cells were collected five days after editing, and genomic DNA was extracted using a DNA kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., DP304) according to the instructions provided by the DNA kit.
[0268] The first round of PCR was performed using 2×Q5 Mastermix. The PCR primers are shown in Table 4 below:
[0269] Table 4: List of primers for the first round of PCR in next-generation sequencing
[0270]
[0271] The reaction system is as follows:
[0272]
[0273]
[0274] The PCR run procedure is as follows:
[0275]
[0276] The second round of PCR for sequencing library construction was performed using 2xQ5 Mastermix. The PCR primers are as follows:
[0277] F2 Primer:
[0278] AATGATACGGCGACCACCGAGATCTACACNNNNNNNNACACTCT TTCCCTACACGAC (NNNNNNNN is the index part);
[0279] R2 Primer:
[0280] CAAGCAGAAGACGGCATACGAGATNNNNNNNNGTGACTGGAGTT CAGACGTGTG (NNNNNNNN is the index part).
[0281] The reaction system is as follows:
[0282]
[0283] The PCR run procedure is as follows:
[0284]
[0285] The second round of PCR products were purified using a gel recovery kit according to the steps provided by the manufacturer to purify the fragments of a specific size. Thus, the preparation of the second generation sequencing library was completed.
[0286] (7) Analysis of Next-Generation Sequencing Results
[0287] The prepared second-generation sequencing library was subjected to double-end sequencing on a high-throughput sequencer HiseqXTen (Illumina).
[0288] The editing efficiency of the A3 target site calculated by the second generation sequencing is as follows Figure 1 As shown, the X-axis represents sgRNAs with different Spacer lengths, and the Y-axis represents editing efficiency (Indels%). As can be seen from the figure, the NiCas12b editing system can be used for cell gene editing, and the editing activity is higher when the Spacer is 24bp.
[0289] Example 2
[0290] (1) Preparation of sgRNA variant plasmids
[0291] In Example 1, a wild-type NiCas12b-sgRNA scaffold sequence (SEQ ID NO: 7) has been constructed, which consists of a full-length direct repeat sequence (repeat) on the bacterial genome and a full-length tracrRNA. The schematic diagram of the sgRNA secondary structure was obtained through RNAfold website analysis. In order to further optimize the sgRNA scaffold sequence, we constructed sgRNA variants according to the secondary structure - truncation 1 (SEQ ID NO: 13, referred to as V1 or V1 variant), truncation 2 (SEQ ID NO: 14, referred to as V2 or V2 variant), truncation 3 (SEQ ID NO: 10, referred to as V3 or V3 variant), truncation 4 (SEQ ID NO: 15, referred to as V4 or V4 variant). Figure 2 As shown, V1 makes the stem-loop pairing more complete by deleting the "AUGU" sequence on stem-loop 2 that does not participate in the stem-loop pairing, thereby stabilizing the stem-loop 2 structure. V2 further truncates the outer stem-loop part of stem-loop 2 on the basis of deleting the unpaired sequence of stem-loop 2. V3 is constructed by truncating the Repeat: Anti-repeat pairing sequence, that is, an outer stem-loop in the Repeat: Anti-repeat pairing region is truncated to make the structure of stem-loop 3 more stable. V4 deletes the unpaired sequence of stem-loop 2 and also truncates the Repeat: Anti-repeat region in the same manner as mutant 3. The bases indicated by the red frame in the figure will pair with the 6bp sequence at the 3' end that does not participate in the formation of the stem-loop. Destroying this pairing relationship will affect the protein editing efficiency. Therefore, all mutants keep the bases in the red frame on stem-loop 2 unchanged.
[0292] The pUC19-NiCas12b-scaffold-sg plasmid (target site A3) with a spacer length of 20 bp in Example 1 (4) was used as a template for PCR reaction, and the primers are shown in Table 5. The V4 variant was obtained by PCR using the V2 primer and then the V3 primer.
[0293] Table 5: PCR primers used to construct NiCas12b-sgRNA scaffold variants
[0294] name sequence V1-F GCGAAAATGCCACGGTGTCTTCCCCTTCAA V1-R TTGAAGGGGAAGACACCGTGGCATTTTCGC V2-F TTGGCACCGTGGAGTCGATCA V2-R ACTCCACGGTGCCAAAAGACACCGTGGCATTTTCGC V3-F TTGATCGACGGACACAGAAGAGC V3-R GTGTCCGTCGATCAAGATCGACTCCACGGTGCCAA
[0295] The PCR reaction system is as follows:
[0296]
[0297] The PCR run procedure is as follows:
[0298]
[0299] The PCR product was electrophoresed on a 1% agarose gel at 120 V for 30 min, and the target DNA fragment was purified using a gel recovery kit according to the manufacturer's steps. TM The DNA concentration was measured by a Thermo Scientific Lite spectrophotometer, and then the purified fragments were subjected to homologous recombination reaction using the ClonExpress Ultra One Step Cloning Kit (Cat. No. C115).
[0300] The recombinant product was added to Escherichia coli DH5α competent cells (purchased from Shanghai Weidi Biotechnology Co., Ltd.), incubated on ice for 30 min, heat shocked at 42°C for 1 min, incubated on ice for 2 min, added with 900 μL LB medium, and cultured at 37°C for 1 hour to activate and resuscitate the Escherichia coli DH5α competent cells.
[0301] The revived E. coli DH5α competent cells were spread on LB solid plates containing ampicillin resistance, and cultured upside down in a 37°C incubator. The obtained E. coli DH5α single clone was verified by Sanger sequencing.
[0302] The E. coli DH5α clones with correct connection verified by sequencing were shaken and plasmids were extracted to obtain sgRNA variant plasmids pUC19-scaffold-V1, pUC19-scaffold-V2, pUC19-scaffold-V3, and pUC19-scaffold-V4, which were set aside or stored at -20°C for long-term storage.
[0303] (2) Co-transfection of HEK293T cell lines with plasmid pAAV-NiCas12b-puro expressing NiCas12b protein and plasmid expressing sgRNA variants
[0304] On day 0, according to the transfection requirements, HEK293T cells (GFP reporter system) containing the target sequence (TTGGGTGAGGGAGGAGAGATGCCCGGAGA) were plated in 48-well plates with a cell density of about 30% (if other well plates are used, the system can be scaled up or down in equal proportion).
[0305] On day 1, transfection was performed. The transfection process was as follows:
[0306] Take 500 ng of pAAV-NiCas12b-puro plasmid and 300 ng of pUC19-scaffold-V1, pUC19-scaffold-V2, pUC19-scaffold-V3 or pUC19-scaffold-V4 plasmid and add them to 12.5 μL Opti-MEM medium (purchased from Gibco), and mix them by gently pipetting.
[0307] Lipofectamine 2000 (purchased from Invitrogen) or polyethyleneimine (hereinafter referred to as PEI) (purchased from Polysciences) was flicked to mix well, and 1.6 μL was drawn. 2000 or PEI was added to 12.5 μL Opti-MEM medium (purchased from Gibco), gently mixed, and allowed to stand at room temperature for 5 min.
[0308] The diluted transfection reagent and the diluted plasmid were mixed, gently pipetted to mix, and allowed to stand at room temperature for 20 minutes, and then added to the culture medium containing the HEK293T cells to be transfected. The cells were then placed in a 37°C, 5% CO2 incubator for further culture for 3 days, and then screened with puromycin (puro) for 5 days.
[0309] (3) Preparation of next-generation sequencing libraries and analysis of next-generation sequencing results
[0310] Step (3) is the same as steps (6)-(7) described in Example 1. The edited cells of different groups are collected and the editing efficiency is analyzed by next-generation sequencing.
[0311] The editing efficiency results of sgRNA variants are shown in Figure 3 As shown by Figure 3 It can be seen that compared with wild-type sgRNA or other variant sgRNA, the V3 variant can significantly improve the editing efficiency of NiCas12b.
[0312] Example 3
[0313] Step (1)
[0314] Step (1) is the same as step (1) described in Example 1 to construct the plasmid pAAV-NiCas12b-puro expressing the NiCas12b protein.
[0315] Step (2)
[0316] Step (2) is the same as step (1) described in Example 2 to construct plasmid pUC19-scaffold-V3, and then proceed with the following steps:
[0317] The plasmid pUC19-scaffold-V3 prepared in (2) was digested with BspQI restriction endonuclease (NEB, catalog number R0712S). The digestion system was: 1 μg of plasmid pUC19-scaffold-V3, 1 μL of BspQI restriction endonuclease, 5 μL of 10×CutSmart buffer (purchased from NEB), and water was added to 50 μL. The digestion system was reacted at 37° C. for 0.5-1 hour.
[0318] Then, the digested products were electrophoresed on 1% agarose gel at a voltage drop of 5 V / cm for 30 min.
[0319] The DNA fragments were cut from the agarose gel and recovered using a gel recovery kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., DP209) according to the manufacturer's instructions, and finally eluted with ultrapure water. The recovered linearized plasmid pUC19-scaffold-V3 was purified by NanoDrop TM The DNA concentration was measured by Lite spectrophotometer (Thermo Scientific) and stored for later use or at -20°C for long-term storage.
[0320] (3) Preparation of sgRNA on-target and mismatch plasmids based on pUC19-scaffold-V3
[0321] The sequences of each on-target gRNA and mismatch gRNA were designed, and the corresponding oligonucleotide single-stranded DNAs were shown in Table 6 below, where the mismatch bases were shown as underlined bold bases in the sequence table.
[0322] Table 6: Oligonucleotide single-stranded DNA corresponding to on-target gRNA and mismatch gRNA
[0323]
[0324]
[0325] The oligonucleotide single-stranded DNA corresponding to the on target gRNA and the oligonucleotide single-stranded DNA corresponding to different mismatch gRNAs were annealed separately. The annealing reaction system was: 1μL 100μM oligo-F, 1μL 100μM oligo-R, and 28μL water. After the annealing system was shaken and mixed, it was placed in a PCR instrument to run the annealing program; the annealing program was as follows: 95℃_5min, 85℃_1min, 75℃_1min, 65℃_1min, 55℃_1min, 45℃_1min, 35℃_1min, 25℃_1min, 4℃ storage, cooling rate 0.3℃ / s. After annealing, the obtained products were connected to the obtained linearized pUC19-scaffold plasmids by DNA ligase (purchased from NEB).
[0326] Take 1 μL of the obtained ligation product and add it to Escherichia coli DH5α competent cells (purchased from Shanghai Weidi Biotechnology Co., Ltd.), incubate on ice for 30 min, heat shock at 42°C for 1 min, incubate on ice for 2 min, add 900 μL LB medium, and culture at 37°C for 1 h to activate and recover the Escherichia coli DH5α competent cells.
[0327] The revived E. coli DH5α competent cells were spread on LB solid plates containing corresponding resistance and cultured inverted in a 37°C incubator. The obtained E. coli DH5α single clone was verified by Sanger sequencing.
[0328] The E. coli DH5α clones with correct connection verified by sequencing were shaken and plasmids were extracted, namely, plasmid pUC19-scaffold-on target gRNA expressing the above-mentioned on target gRNA sequence and plasmid pUC19-scaffold-mismatch gRNA expressing the above-mentioned different mismatch gRNA sequences were obtained for use.
[0329] (4) Co-transfection of plasmids into HEK293T cell lines
[0330] On day 0, according to the transfection requirements, the GFP reporter system HEK293T cell line containing the target sequence was plated in a 48-well plate, and the cell density was controlled at 30% (other well plates can be scaled up or down in the same proportion).
[0331] The GFP reporter system HEK293T cell line containing the target sequence contains the nucleotide sequence of CMV-ATG-PAM-target site-GFP, wherein the PAM sequence is shown in Figure 4 , the sequence of the target site is GGATATGTTGAAGAACACCATGAC.
[0332] On day 1, transfection was performed as follows:
[0333] Take 500 ng of pAAV-NiCas12b-puro and 300 ng of pUC19-NiCas12b-scaffold-ontarget gRNA or 300 ng of pUC19-scaffold-mismatch gRNA and add them to 12.5 μL of Opti-MEM culture medium (purchased from Gibco), and gently pipet to mix.
[0334] Will 2000 (purchased from Invitrogen) or PEI (purchased from Polysciences) was flicked to mix well, and 1.6 μL was drawn. 2000 or PEI was added to 12.5 μL Opti-MEM medium, mixed gently, and allowed to stand at room temperature for 20 min.
[0335] The diluted plasmid and the diluted transfection reagent were mixed and gently pipetted to mix. The resulting mixture was allowed to stand at room temperature for 20 minutes and then added to the culture medium of the GFP reporter system HEK293T cell line containing the target sequence and continued to be cultured in a 37°C, 5% CO2 incubator.
[0336] Flow cytometry analysis technology was used to analyze the editing efficiency and off-target rate of the CRISPR gene editing system of the present invention on the target sequence.
[0337] Specifically, HEK293T cell lines were collected after being cultured in a CO2 incubator for 5 days, and their specificity was detected using a flow cytometer (BD Biosciences FACSCalibur), and the GFP positive ratio was analyzed and plotted using FlowJo analysis software.
[0338] The specific detection results of the CRISPR / NiCas12b gene editing system of the present invention in the HEK293T cell line (GFP reporter system) containing the target sequence are shown in Figure 4, where the upper horizontal bar shows a schematic diagram of the GFP reporter system, with a specific PAM sequence (CGTTG) and target sequence inserted between the start codon ATG and the GFP coding sequence, causing a GFP frameshift mutation. Therefore, when the gene editing system cuts the target sequence, the cell's own repair system will restore the GFP reading frame in some cells, producing green fluorescence. Figure 4 The Y axis in the bar graph at the bottom represents the percentage ratio of GFP positive cells (%), and the X axis represents the oligonucleotide single-stranded DNA sequence corresponding to On-target gRNA and mismatch gRNA. It can be seen that the target sites of the CRISPR gene editing system of the present invention in the HEK293T cell line have all been edited, and the gene editing ratio mediated by mismatch gRNA is significantly lower than the gene editing ratio mediated by on-target gRNA, thereby indicating that the editing activity of the CRISPR gene editing system of the present invention is high, the off-target rate is low, and the specificity is high. And in the research results for the CRISPR / NiCas12b gene editing system, no obvious mismatch phenomenon was found in the single base mismatch of the first 21bp, indicating that the CRISPR / NiCas12b gene editing system has extremely high requirements for the complete pairing between gRNA and the target sequence, with a lower fault tolerance and a higher safety of practical application.
[0339] Example 4
[0340] (1) Construction of plasmids pAAV-NiCas12b-756N, pAAV-NiCas12b-540N, and pAAV-NiCas12b-631N
[0341] The coding sequences of the fusion proteins containing the NiCas12b-756N terminus, the NiCas12b-540N terminus or the NiCas12b-631N terminus and the Npu DnaE N-terminal intein were synthesized, which were SEQ ID NO: 5, SEQ ID NO: 16, and SEQ ID NO: 17, respectively, and constructed into the pAAV-CMV-Hsp2Cas9 plasmid (Addgene platform, catalog #192126) backbone (i.e., between the pCMV promoter and the SV40 terminator, and the Cj gRNA scaffold element on the backbone was deleted at the same time), to obtain plasmids pAAV-NiCas12b-756N, pAAV-NiCas12b-540N and pAAV-NiCas12b-631N (see Figure 5 ).
[0342] (2) Construction of plasmids pAAV-NiCas12b-757C, pAAV-NiCas12b-541C, and pAAV-NiCas12b-632C
[0343] The coding sequences of the fusion proteins containing the Npu DnaE C-terminal intein and the NiCas12b-757C-terminus, NiCas12b-541C-terminus or NiCas12b-632C-terminus were synthesized, which were SEQ ID NO: 6, SEQ ID NO: 18, and SEQ ID NO: 19, respectively, and constructed into the pAAV-CMV-Hsp2Cas9 plasmid (Addgene platform, catalog #192126) backbone (i.e., between the pCMV promoter and the SV40 terminator, and the Cj gRNA scaffold element on the backbone was deleted at the same time), and the plasmids pAAV-NiCas12b-757C, pAAV-NiCas12b-541C, pAAV-NiCas12b-632C (see Figure 5 ).
[0344] (3) Construction of pUC19-scaffold-V3 plasmid
[0345] According to the same procedure as described in Example 2, plasmid pUC19-scaffold-V3 was constructed.
[0346] (4) Construction of plasmid pAAV-NiCas12b-757C / 632C / 541C-U6-scaffold
[0347] PCR was performed on the pUC19-scaffold-V3 plasmid and pAAV-NiCas12b-757C, pAAV-NiCas12b-632C, and pAAV-NiCas12b-541C plasmids, respectively, and the primers are shown in Table 7 below.
[0348] Table 7: PCR primers used to construct plasmid pAAV-NiCas12b-757C / 632C / 541C-U6-scaffold
[0349]
[0350] The PCR reaction system is as follows:
[0351]
[0352] The PCR run procedure is as follows:
[0353]
[0354]
[0355] The PCR product was electrophoresed on a 1% agarose gel at 120 V for 30 min, and the target DNA fragment was purified using a gel recovery kit according to the manufacturer's steps. TM The DNA concentration was measured using a Thermo Scientific Lite spectrophotometer, and then the purified fragments were subjected to homologous recombination reaction using the ClonExpress Ultra One Step Cloning Kit (Cat. No. C115).
[0356] The recombinant product was added to Escherichia coli DH5α competent cells (purchased from Shanghai Weidi Biotechnology Co., Ltd.), incubated on ice for 30 min, heat shocked at 42°C for 1 min, incubated on ice for 2 min, added with 900 μL LB medium, and cultured at 37°C for 1 hour to activate and resuscitate the Escherichia coli DH5α competent cells.
[0357] The revived E. coli DH5α competent cells were spread on LB solid plates containing ampicillin resistance, and cultured upside down in a 37°C incubator. The obtained E. coli DH5α single clone was verified by Sanger sequencing.
[0358] The Escherichia coli DH5α clones with correct connection verified by sequencing were shaken and plasmids were extracted to obtain pAAV-NiCas12b-757C-U6-scaffold, pAAV-NiCas12b-632C-U6-scaffold, and pAAV-NiCas12b-541C-U6-scaffold plasmids, which were set aside or stored at -20°C for long-term storage.
[0359] (6) Linearization preparation of plasmid
[0360] The plasmids prepared in the previous step were subjected to restriction endonuclease (NEB) for digestion reaction. The reaction system was: 2 μg of plasmid pAAV-NiCas12b-757C-U6-scaffold or pAAV-NiCas12b-632C-U6-scaffold or pAAV-NiCas12b-541C-U6-scaffold, 5 μL of 10×CutSmart buffer (purchased from NEB), 1 μL of BsaI restriction endonuclease (purchased from NEB), and water was added to 50 μL. The digestion system was reacted at 37° C. for 0.5-1 hour.
[0361] Then, the digested products were electrophoresed on 1% agarose gel at 120 V for 30 min.
[0362] The DNA fragments were cut out from the agarose gel, recovered using a gel recovery kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., DP209) according to the instructions provided by the manufacturer, and finally eluted with ultrapure water.
[0363] The recovered linearized fragments pAAV-NiCas12b-757C-U6-scaffold, pAAV-NiCas12b-632C-U6-scaffold, and pAAV-NiCas12b-541C-U6-scaffold were purified by NanoDrop TM The DNA concentration was measured by Lite spectrophotometer (ThermoScientific) and kept for later use or at -20°C for long-term storage.
[0364] (7) Construction of plasmids pAAV-NiCas12b-757C-U6-scaffold-sg1, pAAV-NiCas12b-632C-U6-scaffold-sg1, and pAAV-NiCas12b-541C-U6-scaffold-sg1
[0365] The ontarget sequence for the mouse Pcsk9 target site (located in Pcsk9 exon1: GTACCGGGGCCCGTTAATGTTTAA) was designed, and the corresponding oligonucleotide single-stranded DNA is shown in Table 8 below:
[0366] Table 8: Oligonucleotide single-stranded DNA of Pcsk9-on target gRNA
[0367] name sequence PCSK9-sg1-F cacGTACCGGGGCCCGTTAATGTTTAA PCSK9-sg1-R aaaTTAAACATTAACGGGCCCCGGTAC
[0368] Note: The lowercase letters represent the sticky end sequences on both sides of the linearized plasmid pAAV-NiCas12b-757C / 632C / 541C-U6-scaffold.
[0369] Anneal the oligonucleotide single-stranded DNA corresponding to the on target gRNA obtained. The annealing reaction system is: 1μL 100μM oligo-F, 1μL 100μM oligo-R, 28μL water. After the annealing system is shaken and mixed, it is placed in a PCR instrument to run the annealing program; the annealing program is as follows: 95℃_5min, 85℃_1min, 75℃_1min, 65℃_1min, 55℃_1min, 45℃_1min, 35℃_1min, 25℃_1min, 4℃ storage, cooling rate 0.3℃ / s. After annealing, the obtained product is connected to the obtained linearized pAAV-NiCas12b-757C-U6 plasmid by DNA ligase (purchased from NEB).
[0370] Take 1 μL of the obtained ligation product and add it to Escherichia coli DH5α competent cells (purchased from Shanghai Weidi Biotechnology Co., Ltd.), incubate on ice for 30 min, heat shock at 42°C for 1 min, incubate on ice for 2 min, add 900 μL LB medium, and culture at 37°C for 1 h to activate and recover the Escherichia coli DH5α competent cells.
[0371] The revived E. coli DH5α competent cells were spread on LB solid plates containing corresponding resistance and cultured inverted in a 37°C incubator. The obtained E. coli DH5α single clone was verified by Sanger sequencing.
[0372] The E. coli DH5α clones with correct connection verified by sequencing were shaken and the plasmids were extracted to obtain the plasmids pAAV-NiCas12b-757C-U6-sg1, pAAV-NiCas12b-632C-U6-sg1, and pAAV-NiCas12b-541C-U6-sg1 expressing the above-mentioned ontarget gRNA sequences for later use.
[0373] (8) Transfection of Hepa 1-6 cell line for gene editing
[0374] On day 0, Hepa 1-6 cells containing the above target sequence were plated in a 48-well plate according to the transfection requirements, with a cell density of about 50%.
[0375] On day 1, transfection was performed. The transfection process was as follows:
[0376] Take 800 ng of pAAV-NiCas12b-757C-U6-sg1 and 800 ng of pAAV-NiCas12b-756N plasmid, or take 800 ng of pAAV-NiCas12b-541C-U6-sg1 and 800 ng of pAAV-NiCas12b-540N plasmid, or take 800 ng of pAAV-NiCas12b-632C-U6-sg1 and 800 ng of pAAV-NiCas12b-631N plasmid, add to 12.5 μL Opti-MEM medium (purchased from Gibco), and gently pipette to mix.
[0377] Lipofectamine 2000 (purchased from Invitrogen) was flicked to mix, and 3.2 μL was drawn 2000 was added to 12.5 μL Opti-MEM medium (purchased from Gibco), mixed gently, and allowed to stand at room temperature for 1 min.
[0378] The diluted transfection reagent and the diluted plasmid were mixed, gently pipetted to mix, and allowed to stand at room temperature for 20 min. The mixture was then added to the culture medium containing HEK293T cells to be transfected, and the cells were then placed in a 37° C., 5% CO 2 incubator for further culturing for 5 days.
[0379] (9) Preparation of Next-Generation Sequencing Library
[0380] Hepa 1-6 cells were collected 5 days after editing, and genomic DNA was extracted using a DNA kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., DP304) according to the instructions provided by the DNA kit.
[0381] Perform the first round of PCR library construction, use 2×Q5 Master mix for PCR reaction, and the PCR primers are as follows:
[0382] Table 10. List of primers for the first round of PCR in next-generation sequencing
[0383]
[0384] The reaction system is as follows:
[0385]
[0386] The PCR run procedure is as follows:
[0387]
[0388] The second round of PCR for sequencing library construction was performed using 2xQ5 Master mix. The PCR primers are as follows:
[0389] F2 Primer:
[0390] AATGATACGGCGACCACCGAGATCTACACNNNNNNNNACACTCTTTCCCTACACGAC;
[0391] R2 Primer:
[0392] CAAGCAGAAGACGGCATACGAGATNNNNNNNNGTGACTGGAGTT CAGACGTGTG.
[0393] The reaction system is as follows:
[0394]
[0395] The PCR run procedure is as follows:
[0396]
[0397] The second round of PCR products were purified using a gel recovery kit according to the steps provided by the manufacturer to purify 300-400 bp DNA fragments, thereby completing the preparation of the second-generation sequencing library.
[0398] (10) Analysis of Next-Generation Sequencing Results
[0399] The prepared second-generation sequencing library was subjected to double-end sequencing on the high-throughput sequencer HiseqXTen (Illumina).
[0400] The editing efficiency results for the Pcsk9 target site were calculated by the second-generation sequencing, such as Figure 6 As shown, the X-axis represents the NiCas12b protein obtained by each fusion protein, and the Y-axis represents the editing efficiency (Indels%). Figure 6 It can be seen that compared with the NiCas12b wild-type protein, the complete NiCas12b protein formed by expressing the NiCas12b-756N-terminal fusion protein and the NiCas12b-757C-terminal fusion protein still showed a higher gene editing efficiency. In addition, by analyzing the expression of PCSK9 protein, it was found that compared with the NiCas12b protein obtained by other fusion proteins, the amount of PCSK9 protein decreased more significantly after editing the NiCas12b protein obtained by expressing the NiCas12b-756N-terminal fusion protein and the NiCas12b-757C-terminal fusion protein, such as Figure 7 This shows that among the three segmentation methods, segmentation between positions 756 and 757 of the NiCas12b protein is the most efficient, which illustrates the feasibility of the technical solution of the present invention.
[0401] Sequence Listing
[0402] SEQ ID NO: 1: NiCas12b protein sequence (Nitrospira sp.)
[0403]
[0404] SEQ ID NO: 2: Coding sequence of NiCas12b protein
[0405]
[0406] SEQ ID NO:3: Fusion protein sequence containing the N-terminus of NiCas12b-756 and the N-terminal intein of Npu DnaE
[0407] MAPKKKRKVEASMPQEAMPPVTKRAYTLRLRGADPSDTSWREALWKTHEAVNKGAKAFGDWLLTLRGGLDHTLVDTKVKDGKGKSDRDPTPEERKARRILLALSWLSVESRLGAPADFIVAYGTEAAEDRNSKVIAALEEILKSRGLEDTEIAEWKNDCSPSLSAAIRDDAVWVNRSKAFDEAVKGQNKQQGRQDAQTLLWYLLTENYLQLPSKAEKKQSEPLDQEEEEPDSEEISEAVGKSGKGAGQRTRHPFSHIFGKNDNQGFGRPVRQLELRNHWQKHLKPLVEGADIPLKNPNSRAKGETPSPTELHREMFSKAAARLAQIWTKQKKQEVVRELRTAADADLKKLENDQAYCKPLALLNAYCRERGQSVGSLGEYRINPRAVEGWERVVAAWEKIKQTDPAKAAEARIEEAKRLQDEDPDKKFGDINLFINLAEPEYEPVWRHNGQSTPSILKSYVKGWKARSDAVRLKVAAFRHPDPYFHPDFCQFGISRPPIKYNRLKINPRGDPREVQMRLWTGSQAKDITLLAVSNRFDKEIGTIDESTVNPSSNATVVTRRSRLGIASTARLGGSGVFRVAHVFDQQEVRSRKREDQVSSQDQTGGDNSQGGKQKEPTWNGTLQADRRELEAIGKIKDSQKAGKARKRLRWWLTVSLELQQKGPWYDFIGNSSDKTAFTRIYKSGKNKGTEYISQDGWPHERANDTRKGHARLILSRLPGLRVLSVDLGHRYAAACAVWEAVTSEQMKEACKAANHRAPQESDLYLHLKCLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNIYTQPVAQWHDRGEQEVFEYCLEDGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPNSPKKKRKV*
[0408] SEQ ID NO:4: Fusion protein sequence containing the C-terminal intein of Npu DnaE and the C-terminus of NiCas12b-757
[0409] MAIKIATRKYLGKQNVYDIGVERDHNFALKNGFIASNTKGHDGKERTTIYRRIGADTLPDGTEHPAPWARLDRQFLIKLQGEEEGTREASNEEIWRVHQLEAKLGRTVLLIDRLVGAGWGVTEKQKLRIEELKQLGWRPAKDDKPASDVSSEDMGSDGYRLSLAVDELMFSTVRILRLGLKRHGDRARIAHYLITNEKTKPGGIKEQLDENGRLELLQDALALWHDLFSSRGWRDDAARQLWDEHIAKLSGYNAPEEIGEESSGSERKKKQRENRKKLHEAVMVLAQDATLRQKLHDEWKKRWEDDDKEWKQRLRWFKDWVFPRGKAADDPVIRKVGGLSLTRLATLTEFRRKVQLGFFTRLHPDGTRAETKEQFGQSVLDALEHLREQRVKQIASRIVEAALGVGSENPRHWDKGKRPRQRIDDPRFAPCHAIIIEDLTHYRPEETRTRRENRQLMIWSSSKIKKYLAEACQLHGLHLREVQAAYTSRQDSRTGAPGIRCQDVPVKEFMQSPFWRKQVKQAEAKQAENKGDARDRFLCDLNAMWKDKTVADWEKAGVIRVPLNGGEVFVSADPVSPAAKGLQADLNAAANIGLQALTDPDWPGKWWYVPCNPASFRPIKDKVGGSAVVKPDQALRQSAQTQSGDAKDKKKRGKRGDGKPKEVVNLWSDLDTKPLENRNWEEYAAYQHGVLSRVVHVLKKQLKDRHDRRHDEPRADDIPLDYKDHDGDYKDHDIDYKDDDDKSPKKKRKVSRAR*
[0410] SEQ ID NO:5: Coding sequence of a fusion protein containing the N-terminus of NiCas12b-756 and the N-terminal intein of Npu DnaE
[0411]
[0412] SEQ ID NO:6: Coding sequence of a fusion protein comprising Npu DnaE-C-terminal intein and NiCas12b-757C-terminus
[0413]
[0414] SEQ ID NO:7: Scaffold sequence of single-stranded guide RNA
[0415] GCCUCUACAGGAGGCGAAAAUGCCACGGUAUGUGUCUUCCCCUUCAAUGGGCUUGGCACCGUGGAGUCGAUCAGUUUUGUUCCGACGAAGGAGCGCAGCCGAAGUCGGCACCAACUUGAUCGACGGACAC
[0416] SEQ ID NO:8: DNA sequence of the scaffold sequence of the single-stranded guide RNA
[0417] GCCTCTACAGGAGGCGAAAATGCCACGGTATGTGTCTCCCCTTCAATGGGCTTGGCACCGTGGAGTCGATCAGTTTTGTTCCGACGAAGGAGCGCAGCCGAAGTCGGCACCAACTTGATCGACGGACAC
[0418] SEQ ID NO:9: Scaffold sequence of single-stranded guide RNA mutant V3
[0419] GCCUCUACAGGAGGCGAAAAUGCCACGGUAUGUGUCUUCCCUUCAAUGGGCUUGGCACCGUGGAGUCGAUCUUGAUCGACGGACAC
[0420] SEQ ID NO: 10: DNA sequence of the scaffold sequence of the single-stranded guide RNA mutant V3
[0421] GCCTCTACAGGAGGCGAAAATGCCACGGTATGTGTCTCTCCCCTTCAATGGGCTTGGCACCGTGGAGTCGATCTTGATCGACGGACAC
[0422] SEQ ID NO: 11: Amino acid sequence of Npu DnaE-N-terminal intein
[0423] CLSYETEILTVEYGLLPIGKIVEKRIECTVYSVDNNGNIYTQPVAQWHDRGEQEVFEYCLEDGSLIRATKDHKFMTVDGQMLPIDEIFERELDLMRVDNLPN
[0424] SEQ ID NO: 12: Amino acid sequence of Npu DnaE-C-terminal intein
[0425] IKIATRKYLGKQNVYDIGVERDHNFALKNGFIASN
[0426] SEQ ID NO: 13: DNA sequence of the scaffold sequence of single-stranded guide RNA mutant V1
[0427] GCCTCTACAGGAGGCGAAAATGCCACGGTGTCTTCCCCTTCAATGGGCTTGGCACCGTGGAGTCGATCAGTTTTGTTCCGACGAAGGAGCGCAGCCGAAGTCGGCACCAACTTGATCGACGGACAC
[0428] SEQ ID NO: 14: DNA sequence of the scaffold sequence of the single-stranded guide RNA mutant V2
[0429] GCCTCTACAGGAGGCGAAAATGCCACGGTGTCTTTTGGCACCGTGGAGTCGATCAGTTTTGTTCCGACGAAGGAGCGCAGCCGAAGTCGGCACCAACTTGATCGACGGACAC
[0430] SEQ ID NO: 15: DNA sequence of the scaffold sequence of the single-stranded guide RNA mutant V4
[0431] GCCTCTACAGGAGGCGAAAATGCCACGGTGTCTCTCCCCTTCAATGGGCTTGGCACCGTGGAGTCGATCTTGATCGACGGACAC
[0432] SEQ ID NO: 16: Coding sequence of a fusion protein comprising NiCas12b-540 N-terminus and Npu DnaE N-terminal intein
[0433]
[0434] SEQ ID NO: 17: Coding sequence of a fusion protein comprising the NiCas12b-631 N-terminus and the Npu DnaE N-terminal intein
[0435]
[0436] SEQ ID NO: 18: Coding sequence of a fusion protein comprising Npu DnaE-C-terminal intein and NiCas12b-541C-terminus
[0437]
[0438] SEQ ID NO: 19: Coding sequence of a fusion protein comprising Npu DnaE-C-terminal intein and NiCas12b-632C-terminus
[0439]
Claims
1. A fusion protein comprising: a) the NiCas12b protein N-terminus and the intein N-terminus whose amino acid sequence is represented by positions 1-756 of SEQ ID NO: 1; or b) the C-terminus of the NiCas12b protein and the C-terminus of the intein whose amino acid sequence is represented by positions 757-1439 of SEQ ID NO: 1; Preferably, the intein is, for example, a split intein, such as Npu DnaE intein from Nostoc punctiforme, Syn DnaE intein from Synechocystis sp. PCC6803; Preferably, the intein is Npu DnaE intein, the amino acid sequence at the N-terminus thereof is represented by SEQ ID NO: 11, and the amino acid sequence at the C-terminus thereof is represented by SEQ ID NO: 12; Preferably, the amino acid sequence of the fusion protein in a) is as shown in SEQ ID NO: 3; Preferably, the amino acid sequence of the fusion protein in b) is as shown in SEQ ID NO:
4.
2. A conjugate, comprising: a) the fusion protein according to claim 1; b) a detectable marker and / or an additional protein or polypeptide, for example, the additional protein or polypeptide is selected from one or more of an epitope tag, a reporter protein or a nuclear localization signal sequence, a cytosine deaminase, an adenine deaminase, a cytosine methylase DNMT3A and MQ1, a cytosine demethylase Tet1, a transcription activator protein VP64, p65 and RTA, a transcription repressor protein KRAB, a histone acetylase p300, a histone deacetylase LSD1, and an endonuclease FokI; and c) an optional linker for connecting the fusion protein to the detectable label or the additional protein or polypeptide, such as a linker with a length of 1-50 amino acids.
3. A single-stranded guide RNA, comprising a scaffold sequence and a CRISPR spacer sequence from the 5' end to the 3' end, wherein the scaffold sequence is: a) a scaffold sequence shown in SEQ ID NO:7 or SEQ ID NO:9; or b) a sequence modified based on the sequence shown in SEQ ID NO: 7 or SEQ ID NO: 9 and retaining its biological activity; For example, the modification is one or more of base phosphorylation, base sulfurization, base methylation, base hydroxylation, sequence shortening and sequence lengthening; For example, the shortening of the sequence and the lengthening of the sequence include deletion or addition of one, two, three, four, five, six, seven, eight, nine or ten bases relative to the basic sequence; Preferably, the CRISPR spacer sequence is a sequence with a length of 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 nucleotides (preferably 24 nucleotides) and is capable of complementary pairing with the target sequence.
4. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein of claim 1 or the conjugate of claim 2; for example, the isolated nucleic acid molecule comprises the nucleic acid sequence shown in SEQ ID NO: 5 or 6 or a degenerate sequence thereof.
5. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the single-stranded guide RNA of claim 3, such as the nucleic acid sequence shown in SEQ ID NO: 8 or SEQ ID NO:
10.
6. The isolated nucleic acid molecule according to claim 5, further comprising a nucleic acid sequence encoding a NiCas12b protein or a conjugate or fusion protein thereof as shown in SEQ ID NO: 1; in, The conjugate of the NiCas12b protein comprises: a NiCas12b protein, a detectable label or a combination of a detectable label and another protein or polypeptide, and an optional linker for connecting the NiCas12b protein to the detectable label or the other protein or polypeptide; Wherein, the fusion protein of the NiCas12b protein comprises: NiCas12b protein, another protein and polypeptide, and optionally a linker for connecting the NiCas12b protein to the other protein and polypeptide; For example, the additional protein or polypeptide is selected from one or more of an epitope tag, a reporter protein or a nuclear localization signal sequence, a cytosine deaminase, an adenine deaminase, a cytosine methylase DNMT3A and MQ1, a cytosine demethylase Tet1, a transcription activator protein VP64, p65 and RTA, a transcription repressor protein KRAB, a histone acetylase p300, a histone deacetylase LSD1, and an endonuclease FokI; For example, the isolated nucleic acid molecule further comprises the nucleic acid sequence shown in SEQ ID NO: 2 or a degenerate sequence thereof.
7. A vector comprising a nucleic acid sequence encoding the fusion protein of claim 1 or the conjugate of claim 2, for example, the nucleic acid sequence shown in SEQ ID NO: 5 or 6 or a degenerate sequence thereof; For example, the vector is a plasmid vector such as a pUC19 vector, an episome vector, a pAAV2_ITR vector, a retroviral vector, a lentiviral vector, an adenoviral vector or an adeno-associated viral vector.
8. The vector according to claim 7, further comprising a nucleic acid sequence encoding the single-stranded guide RNA according to claim 3, such as the nucleic acid sequence shown in SEQ ID NO: 8 or SEQ ID NO:
10.
9. A vector comprising a nucleic acid sequence encoding the single-stranded guide RNA of claim 3, such as the nucleic acid sequence shown in SEQ ID NO: 8 or SEQ ID NO:
10.
10. The vector according to claim 9, further comprising a nucleic acid sequence encoding a NiCas12b protein or a conjugate or fusion protein thereof having an amino acid sequence as shown in SEQ ID NO: 1; in, The conjugate of the NiCas12b protein comprises: a NiCas12b protein, a detectable label or a combination of a detectable label and another protein or polypeptide, and an optional linker for connecting the fusion protein to the detectable label or the other protein or polypeptide; Wherein, the fusion protein of the NiCas12b protein comprises: NiCas12b protein, another protein and polypeptide, and optionally a linker for connecting the fusion protein with the other protein and polypeptide; For example, the additional protein or polypeptide is selected from one or more of an epitope tag, a reporter protein or a nuclear localization signal sequence, a cytosine deaminase, an adenine deaminase, a cytosine methylase DNMT3A and MQ1, a cytosine demethylase Tet1, a transcription activator protein VP64, p65 and RTA, a transcription repressor protein KRAB, a histone acetylase p300, a histone deacetylase LSD1, and an endonuclease FokI; For example, the vector further comprises the nucleic acid sequence shown in SEQ ID NO: 2 or a degenerate sequence thereof.
11. A CRISPR / Cas12b gene editing system, comprising: 1) A protein component comprising: a) the fusion protein described in a) of claim 1 or the corresponding conjugate described in claim 2, and the fusion protein described in b) of claim 1 or the corresponding conjugate described in claim 2; or b) a NiCas12b protein having an amino acid sequence as shown in SEQ ID NO: 1, or a conjugate or fusion protein thereof; as well as 2) The single-stranded guide RNA of claim 3; Furthermore, the protein component and the single-stranded guide RNA bind to each other to form a complex; in, The conjugate of the NiCas12b protein comprises: a NiCas12b protein, a detectable label or a combination of a detectable label and another protein or polypeptide, and an optional linker for connecting the fusion protein to the detectable label or the other protein or polypeptide; Wherein, the fusion protein of the NiCas12b protein comprises: NiCas12b protein, another protein and polypeptide, and optionally a linker for connecting the fusion protein with the other protein and polypeptide; For example, the additional protein or polypeptide is selected from one or more of an epitope tag, a reporter protein or a nuclear localization signal sequence, a cytosine deaminase, adenine deaminase, a cytosine methylase DNMT3A and MQ1, a cytosine demethylase Tet1, a transcriptional activator protein VP64, p65 and RTA, a transcriptional repressor protein KRAB, a histone acetylase p300, a histone deacetylase LSD1, and an endonuclease FokI.
12. A method for gene editing a target sequence in a cell or in vitro environment, the method comprising: Contacting any of the following (1) to (6) with a target sequence in a cell or in vitro environment: (1) the fusion protein described in a) of claim 1 or its corresponding conjugate described in claim 2, the fusion protein described in b) of claim 1 or its corresponding conjugate described in claim 2, and the single-stranded guide RNA described in claim 3; (2) the isolated nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein described in a) of claim 1 or the corresponding conjugate described in claim 2 according to claim 4, the isolated nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein described in b) of claim 1 or the corresponding conjugate described in claim 2 according to claim 4, and the isolated nucleic acid molecule according to claim 5; (3) The isolated nucleic acid molecule of claim 6; (4) the vector comprising a nucleic acid sequence encoding the fusion protein described in a) of claim 1 or the corresponding conjugate described in claim 2 according to claim 7, the vector comprising a nucleic acid sequence encoding the fusion protein described in b) of claim 1 or the corresponding conjugate described in claim 2 according to claim 7, and the vector according to claim 9; (5) The vector according to claim 10; (6) The CRISPR / Cas12b gene editing system of claim 11; wherein the fusion protein or conjugate recognizes a protospacer-adjacent sequence located at the 5' end of the target sequence and having the sequence 5'-TTN, such as 5'-TTG; For example, the cell is a non-plant cell, such as a prokaryotic cell or an animal cell, and the animal cell is, for example, a mammalian cell such as a human cell; For example, the gene editing includes one or more of gene knockout of the target sequence, site-specific base changes, site-specific insertions, regulation of gene transcription levels, DNA methylation regulation, DNA acetylation modification, histone acetylation modification, single base conversion, and chromatin imaging tracking. For example, the single base conversion includes conversion of the base adenine to guanine, conversion of cytosine to thymine, or conversion of cytosine to uracil.
13. The method according to claim 12, wherein: The guide sequence of the single-stranded guide RNA forms a complete base complementary pairing structure with the target sequence, and forms an incomplete base complementary pairing structure with the non-target sequence; For example, the incomplete base complementary pairing structure includes one or more, for example, two or more, base mismatch structures.
14. A method for expressing a NiCas12b protein having an amino acid sequence as shown in SEQ ID NO: 1 in a cell or in vitro environment, comprising using the following (1) or (2): (1) The isolated nucleic acid molecule according to claim 4 comprising a nucleic acid sequence encoding the fusion protein according to claim 1 a) or the corresponding conjugate according to claim 2, and the isolated nucleic acid molecule according to claim 4 comprising a nucleic acid sequence encoding the fusion protein according to claim 1 b) or the corresponding conjugate according to claim 2; (2) The vector according to claim 7 comprising a nucleic acid sequence encoding the fusion protein according to claim 1 a) or the corresponding conjugate according to claim 2, and the vector according to claim 7 comprising a nucleic acid sequence encoding the fusion protein according to claim 1 b) or the corresponding conjugate according to claim 2.
15. A cell comprising: the isolated nucleic acid molecule of any one of claims 4-6, or the vector of any one of claims 7-10; For example, the cell is a non-plant cell, such as a prokaryotic cell, or an animal cell, such as a mammalian cell such as a human cell.
16. A kit for gene editing a target sequence in a cell or in vitro environment, comprising: a) Any one selected from the following (1) to (6): (1) the fusion protein described in a) of claim 1 or its corresponding conjugate described in claim 2, the fusion protein described in b) of claim 1 or its corresponding conjugate described in claim 2, and the single-stranded guide RNA described in claim 3; (2) the isolated nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein described in a) of claim 1 or the corresponding conjugate described in claim 2 according to claim 4, the isolated nucleic acid molecule comprising a nucleic acid sequence encoding the fusion protein described in b) of claim 1 or the corresponding conjugate described in claim 2 according to claim 4, and the isolated nucleic acid molecule according to claim 5; (3) The isolated nucleic acid molecule of claim 6; (4) the vector comprising a nucleic acid sequence encoding the fusion protein described in a) of claim 1 or the corresponding conjugate described in claim 2 according to claim 7, the vector comprising a nucleic acid sequence encoding the fusion protein described in b) of claim 1 or the corresponding conjugate described in claim 2 according to claim 7, and the vector according to claim 9; (5) The vector according to claim 10; (6) The CRISPR / Cas12b gene editing system of claim 11; as well as b) Instructions for performing gene editing on the target sequence in cells or in vitro.
